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Molecular Mechanism of Aurora-A Kinase in Human Oncogenesis

Lili He

ABSTRACT

Aurora-A is a mitotic kinase, which regulates cell cycle progression through modulating
centrosome function. Aurora-A expression is frequently altered in human malignancies.
The discrepancy between overexpression and amplification suggests that elevated
Aurora-A level is likely to be regulated also by transcriptional and/or translational
modifications. In this study, we have demonstrated: 1) transcriptional regulation of
Aurora-A by E2F3; 2) feedback regulation between tumor suppressor CHFR and AuroraA; 3) CNTD2 as a novel Aurora-A partner and oncogene to activate Aurora-A and induce
transformation.
Aurora-A expression and activity are cell cycle regulated. The mechanism of
Aurora-A upregulation at onset of mitosis is largely unknown. We demonstrated, for the
first time, that transcription factor E2F3 directly binds to Aurora-A promoter and tightly
regulates Aurora-A expression during G2/M phase. Moreover, expression of E2F3
considerably correlates with Aurora-A level in human ovarian cancer, indicates that E2F3
is a causal factor for Aurora-A overexpression. Thus, E2F3-Aurora-A axis could be an
important target for cancer intervention. The frequent inactivation of prophase checkpoint
CHFR caused by DNA methylation or mutation has been reported in human cancers. We
showed that CHFR is hypermethylated in ovarian carcinoma. Aurora-A phosphorylates
CHFR on Ser-218 and Ser-337 in vivo and in vitro, which inhibits CHFR ubiquitin ligase
activity. The feedback regulation loop between Aurora-A and CHFR could play a critical
viii

role in regulation of cell cycle progression, imbalance of which may contribute to human
oncogenesis. Using yeast 2-hybrid screening, we identified a splicing form of CNTD2 as
Aurora-A interacting protein. CNTD2 locates to chromosome 19q13.2 AKT2 amplicon.
CNTD2 is amplified and overexpressed in human ovarian, pancreatic and lung cancer
cell lines and primary tumors. CNTD2 colocalizes and interacts with Aurora-A in the
centrosome. CNTD2 expression induces Aurora-A and cdc2 kinase activity, G2/M
progression, and malignant transformation. These data indicate that CNTD2 is an
oncogene and could play a pivotal role in Aurora-A activation during the cell cycle and
that disruption of CNTD2-Aurora-A axis may represent a potential means to antitumor
drug discovery.
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CHAPTER I
INTRODUCTION: MOLECULAR MECHANISM OF AURORA-A KINASE IN
HUMAN ONCOGENESIS
Aurora Kinases
Homologues of Aurora/Ipl1-related kinase have been reported in various organisms
including yeast, nematodes, fruit flies and vertebrates (1-3). In mammals, this subfamily
of serine/threonine kinases comprises three members: Aurora-A, -B and -C (4).
Drosophila melanogaster and Caenorhabditis elegans express homologues of Aurora-A
and -B, whereas Saccharomyces cerevisiae and Schizosaccharomyces pombe have only
one Aurora kinase gene (5,6), suggesting that the functions of Auroras have diverged
throughout evolution.
Structure
All Aurora kinases share similar structures, with their catalytic domains flanked by very
short (15–20 residues) C-terminal tails and N-terminal domains of variable lengths (39–
129 residues). The overall homology between these three isoforms in human is about
80% at amino acid level. The central catalytic kinase domain is considered highly
conserved. However, it is interesting to note that Aurora-C and -B share 77.6% amino
acid sequence identity, while Aurora-C and -A share about 66.5% sequence identity (7),
suggesting a functional relationship between Aurora-B and -C. The N-terminal and the Cterminal sequences of the three members are quite different. The C-terminal domain of
human Aurora-B shares 53% and 73% sequence similarity to human Auroras-A and -C,
respectively. The N-terminals of Auroras-A, -B and -C share low sequence conservation,
which may determine the selectivity during protein–protein interactions. Aurora-A N1

terminal domain serves as a localization domain, which targets the protein to the
centrosome in a microtubule dependent manner. The unique A-box motif at the Nterminal of Aurora-A is required for proteolysis of the protein. Furthermore,
phosphorylation of Ser 51 at N-terminal decides the timing of Aurora-A destruction (8).
(see Fig. 1.1)

Fig. 1.1. Aurora kinase family. Diagrammatic representation of the domain structure of
three Aurora family members. The percentages indicate the degree of the identity
between Aurora-A, Aurora-B and Aurora-C.
Localization and Timing of Activation
Despite these similarities, the three mammalian Aurora family members differ in their
expression patterns, subcellular localization, and timing of activity. (see Fig. 1.2)
Aurora-A is first detected at the centrosome during late S phase. The activation of
a small proportion of Aurora-A at centrosomes was first evident before chromosome
condensation at late G2 phase (9). Both the amount and activity of Aurora-A rapidly
increase in the centrosome, and a fraction of active Aurora-A subsequently translocates
into the nucleus coincident with chromatin condensation at prophase. After nuclearenvelope breakdown (NEBD), activated Aurora-A is observed at the spindle poles and
bipolar spindles during prometaphase and metaphase. The amount of Aurora-A starts to
decrease at the metaphase-anaphase transition, whereas a small fraction of Aurora-A
remains on the centrosomes and the spindles at the onset of anaphase and telophase
2

(10,11). Aurora-A is degraded by the cdh1/Fizzy-related form of the anaphase-promoting
complex/cyclosome (APC/C). At the final stage of cytokinesis, most of the Aurora-A
protein becomes undetectable.
Aurora-B, whose activity appears to reach maximal levels later in mitosis,
displays the dynamic properties of a chromosomal passenger protein. It first associates
with centromeres/kinetochores — the sites on chromosomes where microtubules attach
— then relocalizes to the midzone of the central spindle, and finally concentrates at the
midbody between dividing cells (12).

Fig. 1.2. Localization of Aurora-A and -B kinases during the cell cycle. Nature
Reviews Cancer 5, 42-50. January 2005.

3

In line with these distinct localizations, Aurora-A is implicated primarily in
centrosome maturation and spindle assembly (5,6), whereas Aurora-B is proposed to
regulate chromosome condensation and cohesion, kinetochore assembly and bipolar
chromosome attachment, the spindle checkpoint and the coordination between
chromosome segregation and cytokinesis (13-16).
Aurora-C has been described only in mammals, where it is expressed in testis and
certain tumor cell lines and, like Aurora-B, functions as a chromosomal passenger, which
co-localizes with Aurora-B first to centromeres and then to the midzone of mitotic cells.
It has been shown recently that Aurora-C cooperates with Aurora-B to regulate mitotic
chromosome segregation and cytokinesis (17).
Chromosome Location and Involvement in Human Cancer
Human Aurora-A is located at chromosome 20q13.2, which is commonly amplified in
various epithelial malignant tumors, including breast, colon, bladder, ovarian and
pancreatic cancers (18-22). In breast cancer in particular, the 20q11-q13 region is
amplified in 12-18% of primary tumors. The 20q13 amplification is also detected in 5%
(4/72) of gastric cancer from 3.5- to 6.3- fold, and in 52% (41/79) of primary colorectal
tumors.
The levels of Aurora-A mRNA and protein are also increased in those tumors.
However, alterations of Aurora-A at mRNA and/or protein levels are much common than
the gene amplification. For example, amplification of Aurora-A was detected in only 3%
of hepatocellular carcinomas (HCCs) while more than 60% of HCCs overexpressed
Aurora-A mRNA and protein (23). Discrepancy between amplification and
overexpression rates was also reported in breast cancer (24), gastric cancer (25) and
ovarian cancer (21). Therefore, Aurora-A overexpression is likely to be regulated not
only by gene amplification, but also by other mechanisms such as transcriptional
activation and suppression of protein degradation.
Unlike Aurora-A, Aurora-B coding gene, which is mapped to chromosome
17p13.1, is not amplified in human tumors. However, both mRNA and protein levels of
Aurora-B are frequently increased in various human tumors, including colorectal cancers
4

(26,27). Furthermore, exogenous overexpression of Aurora-B in Chinese hamster embryo
cells causes chromosome separation defects during mitosis and increased invasiveness of
cells in vivo, indicating a role for Aurora-B in tumorigenesis (28).
A gene encoding Aurora-C is localized at chromosome 19q13.43, which is the
region frequently deleted or rearranged in several tumor tissues (29). However, the
involvement of Aurora-C in cancer development is still unclear.
Aurora-A, but not Aurora-B and -C, Induces Transformation, Centrosome
Amplification and Genetic Instability
Ectopic expression of Aurora-A, but not Aurora-B and -C, in Rat1 or NIH3T3 cells
results in malignant phenotype, including growing in soft agar and forming tumor in nice
mouse, demonstrating that Aurora-A is an oncogene. Overexpression of Aurora-A leads
to disrupt cell-cycle checkpoint functions. Normal cells have cell-cycle checkpoints that
monitor genomic integrity and prevent cells from dividing in the presence of DNA
damage. Recent studies have shown that DNA-damage signals inhibit Aurora-A kinase
activity to induce cell-cycle arrest at the end of the G2 phase and that, conversely,
overexpression of Aurora-A disrupts the DNA-damage-induced G2 checkpoint (30).
Additionally, Aurora-A overexpression has been found to override the spindle checkpoint
activated by the chemotherapeutic agent paclitaxel (Taxol), allowing cells to
inappropriately enter anaphase despite defective spindle formation and to become
resistant to paclitaxel-induced apoptosis (31). Many experiments have demonstrated the
requirement for Aurora-A in centrosome regulation. In Drosophila, Aurora-A mutants
show several centrosome defects that were confirmed by RNA-mediated interference
(RNAi) (32). Aurora-A overexpression in cell lines leads to centrosome amplification,
multipolar spindle and polyploidy. These checkpoint defects and genetic instability,
caused by Aurora-A overexpression, might contribute to transformation.
Aurora-A Kinase Activity is Required for Its Oncogenic Activity
Transient expression of active Aurora-A in the near diploid human breast epithelial cell
line MCF10A leads to aberrant chromosome segregation and an increase in ploidy (24).
5

In contrast, a C-terminal-deleted mutant of Aurora-A induces no effect in the ploidy state
of transfected gastric cancer cells, but inhibits cell proliferation (25). However,
surprisingly, an inactive Aurora-A kinase produces virtually identical phenotypes to the
wild-type active kinase when overexpressed in Chinese hamster ovary cells (33). Both
transfected cells exhibit extra copies of centrosomes. However such inactive Aurora-A is
unable to transform Rat1 or NIH3T3 cells, strongly indicating that (1) a gain of Aurora-A
kinase activity is necessary to transform cells, and that (2) centrosome amplification is
not sufficient to provoke transformation (19). Thus, overexpression of the Aurora-A
kinase is able to induce centrosome amplification, but its kinase activity is not necessary
to obtain this phenotype. It is possible that the accumulation of the protein leads to a
disorganization of the centrosome machinery unrelated to its catalytic function but caused
by a steric accumulation that interferes with the centrosomal functions.
In contrast, the kinase activity of Aurora-A is necessary to obtain the transformed
phenotype by overexpression in cultured cells. Thus centrosome amplification induced by
Aurora-A overexpression is not sufficient for its oncogenic activity. Under
overexpression, Aurora-A might phosphorylate substrates unrelated to the centrosome
function but involved in oncogenesis. Furthermore, this suggests that kinase activity of
Aurora-A is essential for its oncogenic activity. In addition to elevated levels of mRNA
and protein, we have demonstrated frequent activation of Aurora-A in human prostate
and ovarian cancers, indicating that activation of Aurora-A may be important for
development of these subsets of tumors.
Aurora-A and Mitosis
In the process of separating replicated genetic materials into two daughter cells during
mitosis, cells undergo centrosome maturation, chromosome condensation, nuclearenvelope breakdown, centrosome separation, bipolar-spindle assembly, chromosome
segregation and cytokinesis. Studies in lower organisms have shown that these events are
controlled by phosphorylation events performed by several serine/threonine kinases,
known as mitotic kinases (4). Mitotic kinases include cyclin dependent kinase 1 (CDK1;
6

also known as p34cdc2), polo-like kinases, NIMA-related kinases, WARTS/LATS1related kinases and Aurora/Ipl1-related kinases. The structure of these enzymes has been
well conserved through evolution. Elucidation of how these mitotic kinases are
coordinated will provide a clue to the regulation of cell division.
In human cells, Aurora-A levels and kinase activity increase during late G2 to M
phase, and it undergoes dynamic changes in subcellular localization throughout the cell
cycle. This dynamic localization pattern indicates that Aurora-A is involved in various
mitotic events. In fact, several substrates and/or interacting proteins of Aurora-A
identified recently have been shown to have a crucial role in mitotic processes (Table 1.).
Table 1. Aurora substrates/interacting proteins and mitotic processes.

* Interacting protein that is also Aurora-A substrate.

7

Centrosome Maturation
The centrosome is the primary microtubule nucleating centre within most animal cells at
all stages of the cell cycle, but on entry into mitosis, microtubule assembly at the
centrosome dramatically increases in a process termed maturation. This activation
enables microtubules to grow out from the centrosome, interact with chromosomes and
form the bipolar spindle required for chromosome segregation. At the same time, many
proteins are recruited to centrosomes, including the γ- tubulin ring complex and other
microtubule regulators.
Aurora-A has been shown to be essential for the process of centrosome
maturation in various organisms such as Caenorhabditis elegans and Drosophila
melanogaster (32,34,35). Also, in cultured human cells, Aurora-A depletion results in the
inhibition of centrosome maturation (9).
The discovery of phosphorylation of a conserved centrosomal protein TACC
(Transforming Acidic Coiled-Coil) by Aurora-A could partly explain the molecular
nature of Aurora-A regulation of centrosomal microtubule assembly (32,36,37).
Phosphorylation by Aurora-A recruits TACC, and consequentially its binding partner
Msps/XMAP215 to the centrosome in mitosis (38). Targeting of TACC–Msps/XMAP215
to the centrosome may enhance the activity of Msps/XMAP215 in stabilizing
microtubule plus ends (1). In another model, the phosphorylation is proposed to allow the
complex to stabilize the minus ends of microtubules nucleated at the centrosome (2) (see
Fig. 1.3).
Other than for microtubule assembly, C. elegans homologue of Aurora-A kinase
AIR-1 is required for centrosome maturation by recruiting centrosomal γ-tubulin and two
other PCM (pericentriolar material) components, ZYG-9 and CeGrip, as embryos enter
mitosis (34).

8

Fig. 1.3. Aurora-A regulation of centrosomal microtubule assembly. MT,
microtubules; γ-TuRC, γ-tubulin ring complex. JCB, Volume 170, Number 7, 1039-1046.
2005.
Centrosome Separation
Depletion of AIR-1 in C. elegans doesn’t affect centrosome separation before nuclearenvelope breakdown (NEBD); however, subsequent to NEBD the two asters collapse
back together and remain unseparated, indicating that AIR-1 is not necessary for initial
separation of centrosomes but is required to maintain centrosome separation during
spindle assembly (34). In human cells (HeLa cells), micro-injection of affinity-purified
Aurora-A antibody at late G2 phase inhibits separation of centriole pairs at prophase.
Meanwhile, abnormally organized spindles with no centrioles at one pole and two pair of
centrioles at the other are frequently noticed (10).
It was previously shown that the Xenopus Aurora-related kinase Eg2
phosphorylates the kinesin-like protein XlEg5, which is required for centrosome
separation (39). Therefore it is reasonable to speculate that human Aurora-A might also
regulate separation of centriole pairs through the phosphorylation of kinesin-like motors
during prometaphase.

9

Mitotic Commitment
Analysis of HeLa cells has revealed that the initial active form of Aurora-A is first
detected in late G2 phase at the centrosome. Application of RNA interference (RNAi) to
synchronized cells has shown that this activation is required for the recruitment of
CDK1–cyclin B1 to the centrosome, where it is fully activated and commits cell to
mitosis. A LIM protein called Ajuba was identified as a substrate and an activator for
Aurora-A during mitotic commitment. Depletion of Ajuba prevents activation of AuroraA at centrosomes in late G2 phase and inhibits mitotic entry (9).
Additionally, it has recently been demonstrated that Aurora-A phosphorylates
Ser353 of the phosphatase CDC25B — an activator of cyclin-dependent kinases — at
centrosomes during late G2 phase, also contributing to the onset of mitosis (40).
However, the activation of CDK1–cyclin B1 is in turn required for full activation of
Aurora-A at the centrosome and nucleus (9). These findings indicate that the coactivation of Aurora-A and CDK1 at late G2 centrosomes constitutes an essential early
event in the progression of cells towards mitosis.
Bipolar Spindle Assembly
The role of Aurora-A in mitotic-spindle assembly was initially revealed through studies
in Xenopus egg extracts (41), where the phosphorylation and activation of Eg2 (Xenopus
Aurora-related kinase) stimulated by the Ran-GTP-TPX2 pathway is essential for spindle
assembly; a catalytically inactive pEg2 stops the assembly of bipolar mitotic spindles
(42-44).
TPX2 (Targeting Protein for XKLP2) was isolated from Xenopus as a
microtubule-associated protein, which is required for the recruitment of XKLP2
(Xenopus kinesin-like protein) to microtubules (45). GTP-binding Ran (the small
GTPase) is known to be required for the induction of spindle formation by chromosomes
in M phase. And the action of Ran-GTP in spindle formation requires TPX2 (46).
Depletion of TPX2 from Xenopus egg extracts resulted in the formation of less compact
spindles and a range of pole (47). Additionally, in mammalian cells, depletion of TPX2
using small interfering RNA caused the formation of multipolar spindles (48).
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Furthermore, TPX2 was found to interact with Aurora-A and to be not only a substrate
but also an activator for Aurora-A. Inhibition of the interaction between TPX2 and
Aurora-A prevents Aurora-A activation and recruitment to microtubules (49,50). Earlier
evidences established that depletion of Aurora-A disrupts the stability of the mitotic
spindle in Xenopus eggs and causes the formation of multipolar spindles in mammalian
cells, similar to depletion of TPX2 (41,51). This indicates that the interaction between
TPX2 and Aurora-A could be an important prerequisite for efficient mitotic-spindle
formation. (see Fig. 1.4)

Fig. 1.4. Regulation of Aurora-A activity by Ran–GTP and TPX2. Nature Reviews
Molecular Cell Biology 4, 842-854. November 2003.
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Chromosome Alignment on the Metaphase Plate
Studies have shown that Aurora-B is required for the correct kinetochore-microtubule
attachment between sister chromatids to spindle poles (52,53). The proper interaction
generates the amphitelic attachment state, which is required for accurate chromosome
alignment and segregation (12). However, it has been recently shown that Aurora-A is
also directly involved in metaphase chromosome alignment, by phosphorylating a
kinetochore-specific histone H3 variant CENP-A, which is crucial for kinetochore
assembly and function (54). CENP-A is phosphorylated on the amino-terminal serine
(Ser7) by Aurora-A, and this phosphorylation is important for not only the proper
attachment of microtubules to the kinetochore but also the consequent chromosome
alignment and segregation. Given that post-translational modifications of the aminoterminal tail domain of core histones are known to regulate chromatin structure and
function (55), phosphorylation of Ser7 of CENP-A by Aurora-A might be a crucial event
for kinetochore function. Although Aurora-B is also found to phosphorylate CENP-A at
the same site (56), it is believed that Aurora-A phosphorylation is an earlier and more
important event. Ser7 of CENP-A is first phosphorylated during prophase in a manner
dependent on Aurora-A, and that this reaction is required for the subsequent Aurora-Bdependent phosphorylation of CENP-A as well as the recruitment of Aurora-B to the
inner centromere, where Aurora-B maintains the phosphorylation of CENP-A from
prometaphase through metaphase (54). The phosphorylation of CENP-A on Ser-7 is
required to initiate kinetochore assembly by recruiting several components important for
the establishment of kinetochore-microtubule connections. The two Aurora kinases
therefore regulate kinetochore functions by phosphorylating this common substrate.
Cytokinesis
Both Aurora-A and Aurora-B seem to be involved in cytokinesis. Inhibition of Aurora-B
function results in cytokinesis failure in mammalian cells (13,57-60). Inhibition of
Aurora-A by antibody microinjection in metaphase HeLa cells, which have completed
centrosome separation, bipolar spindle assembly and chromosome alignment, causes
cytokinesis failure; chromosomes are able to segregate, but the daughter cells eventually
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fuse to form binucleate cells (10). It is thus possible that Aurora-A has some direct
function in cytokinesis. The other possibility is that Aurora-A leads to cytokinesis defect
by dysregulation of centriole behavior, which is proposed tightly connected with the
completion of cell division. Interestingly, overexpression of Aurora-A also impairs
cytokinesis, resulting in formation of multinucleated cells (31,33).
As both the inhibition and the increased activity of Aurora-A lead to
multinucleated cell formation, proper timing of activation and subsequent inactivation of
this kinase is required for proper cytokinesis. The reduction of Aurora-A levels at late
mitosis is mediated by ubiquitin-proteasome-mediated degradation, which is promoted by
the anaphase-promoting complex (APC/C) activated by Cdh1 (61,62). This rapid
degradation of Aurora-A resulting in Aurora-A inactivation and dephosphorylation of the
specific substrates, might be required for completion of cytokinesis.
Aurora-A Signaling
Aurora-A regulates a handful of important signal molecules, including cross-talk with
p53 and c-Myc pathways, leading to cell cycle progression, cell proliferation and cell
survival.
p53
Aberrations in centrosome numbers have long been implicated in aneuploidy and
tumorigenesis. Overexpression of Aurora-A kinase causes centrosome amplification in
cultured cells. It does not deregulate centrosome duplication but gives rise to extra
centrosomes through defects in cell division and consequent tetraploidization (33). Over
expression of other mitotic kinases (Polo-like kinase 1 and Aurora-B) also causes
multinucleation and concomitant increases in centrosome numbers (63,64). The
accumulation of extra copies of centrosomes is strikingly enhanced in p53–/– cells,
consistent with the notion that p53 arrests tetraploid cells as part of a G1 checkpoint
(65,66). A study in yeast and human cell lines (HEK293, H1299) showed that Aurora-A
interacts with p53 through Aurora-Box in vivo and in vitro (67). And the interaction
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resulted in the suppression of Aurora-A oncogenic activity regarding centrosome
amplification and cellular transformation by p53 in a transactivation-independent manner.
Our lab has demonstrated, on the other hand, that p53 is phosphorylated and regulated by
Aurora-A (68). Unlike most identified phosphorylation sites of p53 that positively
associate with p53, the phosphorylation of p53 by Aurora-A at Ser-215 abrogates p53
DNA binding and transactivation activity. Downstream target genes of p53, such as
p21Cip/WAF1 and PTEN, were inhibited by Aurora-A in a Ser-215 phosphorylationdependent manner. As a result, Aurora-A overrides the apoptosis and cell cycle arrest
induced by cisplatin and γ-irradiation, respectively. However, the effect of Aurora-A on
p53 DNA binding and transactivation activity was not affected by phosphorylation of
Ser-315, a previously identified Aurora-A phosphorylation site of p53. We have also
reported that Aurora-A protects ovarian cancer cells from apoptosis induced by
chemotherapeutic agent and activates Akt pathway in a p53-dependent manner (69).
c-Myc
Aurora-A plays a pivotal role in transformation, however, the molecular mechanism by
which Aurora-A induces ovarian and breast cell transformation remains elusive. We
found that Aurora-A induces telomerase activity and human telomerase reverse
transcriptase (hTERT) by up-regulation of c-Myc (70). Ectopic expression of Aurora-A
activity in human ovarian and breast epithelial cell lines HIOSE118 and MCF-10A
induces telomerase activity. The mRNA and promoter activities of hTERT are stimulated
by Aurora-A. Furthermore, c-Myc binding sites of hTERT promoter are required for
Aurora-A-induced hTERT promoter activity. Ectopic expression of Aurora-A upregulates c-Myc. Knockdown of c-Myc by RNA interference attenuates Aurora-Astimulated hTERT expression and telomerase activity.
Regarding the mechanism of Aurora-A upregulation of c-Myc, our data
(unpublished) show that Aurora-A inactivates GSK3β through a phosphorylationdependent manner, which leads to β-catenin cytoplasmic accumulation, nuclear
translocation and subsequently activates c-Myc transcription by forming complex with
TCF/LEF transcription factors. We believe that knockdown of c-Myc may reduce
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Aurora-A-induced transformation and genomic instability, but not necessarily abrogate
Aurora-A oncogenic activity. It has been well documented that c-Myc plays a critical role
in human oncogenesis by regulation of cell proliferation and differentiation. Thus,
Aurora-A up-regulation of c-Myc may play an essential role in Aurora-A-induced
malignant transformation in addition to its G2/M cell cycle control.
AR and ER
We have recently shown frequent activation/overexpression of Aurora-A kinase in human
primary prostate tumors (unpublished data). Constitutively active Aurora-A exhibits more
oncogenic activity. Therefore, activation and/or overexpression of Aurora-A could play
an important role in prostate cancer development. In addition, our preliminary study
shows that Aurora-A phosphorylates androgen receptor (AR) in vitro and in vivo and
activates AR transactivation activity, which might contribute to androgen-independent
tumor growth. According to our data, Aurora-A activation of AR could be
phosphorylation dependent. Ectopic expression of Aurora-A in prostate cancer cells may
lead to more aggressive phenotype and androgen-independent growth; whereas
knockdown of Aurora-A could interfere with androgen dependence.
As Aurora-A is frequently altered in breast cancer and induces telomerase activity
and tamoxifen resistance in mammary epithelia (unpublished data); we reasoned that
Aurora-A could regulate ERα activity. Reporter assay showed that ERE-Luc activity is
induced by Aurora-A in a dose-dependent manner in only ERα positive cells. Further,
Aurora-A exhibits synergistic effect with estrogen on ERα transactivation activity. In
addition, we have demonstrated ERα is phosphorylated by Aurora-A in vitro and in vivo
(data not shown). We have also observed that tamoxifen downregulated Bcl-2 is
overridden by Aurora-A, especially constitutively active Aurora-A. These data indicate
important function of Aurora-A besides cell cycle control.
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Aurora-A and Tumorigenesis
Several mechanisms exist by which Aurora-A overexpression might contribute to
tumorigenesis. (see Fig. 1.5)

Fig. 1.5. Mechanisms of Aurora-A promoted tumorigenesis. Nature Reviews Cancer
5, 42-50. January 2005.
Centrosome Amplification and Aneuploidy
Centrosome alterations, including centrosome amplification, are found in brain, breast,
lung, colon, prostate, pancreas, bile duct, head and neck tumors and lymphoma (71-77).
Overexpression of Aurora-A causes centrosome amplification in both cell culture and rat
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mammary models (78,79). However, the phenomenon seems not due to centrosome
duplication but a result of cytokinesis failure and consequent multinucleation (33). Since
both Aurora-A and Aurora-B are shown to be involved in cytokinesis, it is possible that
Aurora-A causes cytokinesis failure directly, or by affecting Aurora-B or other proteins
that regulate cytokinesis. The other possibility is that Aurora-A leads to cytokinesis
defect by dysregulation of centriole behavior, which is proposed tightly connected with
the completion of cell division.
Aneuploidy is thought to be a marker of tumor progression and prognosis.
Correlation between Aurora-A overexpression and aneuploidy exists in gastric and colon
cancer (25,78). Aurora-A-induced polyploid cells would be arrested at the following G1
phase by a post-mitotic checkpoint dependent on the p53/Rb pathway. The G1
checkpoint is required for the cell to trigger apoptosis. However, when these is no
functional p53 present, as in p53-/- cells, the hyperploidy is not detected and cells go on
DNA replication and cell division, which might eventually cause aneuploidy and
abnormal centrosome number (33,80).
Checkpoint Disruption and Chromosome Instability
Overexpression of Aurora-A tends to disrupt cell-cycle checkpoint functions. Normal
cells have cell-cycle checkpoints that monitor genomic integrity and prevent cell dividing
in the presence of DNA damage. Recent studies have shown that DNA-damage signals
inhibit Aurora-A kinase activity to induce cell-cycle arrest at the end of the G2 phase and
that, conversely, overexpression of Aurora-A disrupts the DNA-damage-induced G2
checkpoint (30).
Additionally, Aurora-A overexpression has been found to override the spindle
checkpoint, allowing cells to inappropriately enter anaphase despite defective spindle
formation. Upon activation of the spindle checkpoint, Bub and Mad proteins become
localized to unattached kinetochores. The concentration of these checkpoint proteins on
the kinetochore facilitates the assembly of an active checkpoint complex, which consists
of Cdc20, BubR1, Mad2 and Bub3 (81,82). This complex has the ability to inhibit the
function of anaphase-promoting complex/cyclosome (APC/C). Overexpression of
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Aurora-A leads to a dramatic accumulation in the Cdc20 complex, where BubR1 level is
decreased. At the same time, Mad2 and Bub3 can not be efficiently recruited to Cdc20
complex while the expression of both proteins is not changed (83). The dissociation of
these checkpoint proteins from Cdc20 results in the prematurely activation of APC/C and
bypass of the checkpoint function. Aurora-A plays a critical role in cell cycle checkpoints
to ensure the faithful duplication and transmission of genetic materials. Perturbation of
this regulatory process will endanger genetic stability and possibly contribute to
tumorigenesis.
Polymorphism
Aurora-A was recently identified as a candidate low-penetrance tumor-susceptibility
gene. The involvement of two polymorphisms of Aurora-A (Phe31Ile and Val57Ile) in
human tumor susceptibility was analyzed. The Ile31 allele of Phe31Ile was found to be
preferentially amplified in human colon and ovarian cancers (84,85), and the combination
of the two polymorphisms (31Ile and 57Val) was related to a significant twofold excess
in the risk of breast cancer (86). This genetic evidence also supports the role of Aurora-A
as a tumor modifier gene.
Aurora-A Inhibitors
The evidence linking Aurora overexpression and malignancy has stimulated interest in
developing Aurora inhibitors for cancer therapy. Aurora-A is considered the principal
member of the Aurora family with oncogenic activity. Studies have shown a specific role
of Aurora-A in cancer development and progression. However, an in vivo study of
Aurora inhibitors demonstrated that it is not Aurora-A but Aurora-B inhibition induces
tumor regression. Dual inhibition of Aurora-A and -B results in phenotypes identical to
inactivation of Aurora-B alone (87). Inactivation of Aurora-B bypasses the requirement
for Aurora-A and leads to polyploidy, indicating that Aurora-B is responsible for mitotic
arrest in the absence of Aurora-A (88). Therefore, it is possible that the better antitumor
drug should inhibit all Aurora members instead of only one.
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Many Aurora-selective small-molecule inhibitors are currently undergoing
preclinical and clinical assessment. VX-680 is a pyrimidine derivative, designed against
the ATP-binding site, with affinity for Aurora-A, -B, and -C. VX-680 prevents
cytokinesis but allows cells to progress through the other stages of mitosis, which leads to
polyploidy and, in some cancer cell lines, massive apoptosis. In preclinical models, VX680 blocked tumor growth in three xenograft models, including leukemia, colon and
pancreatic (87). AZD1152 is a quinazoline prodrug, which is converted in plasma into its
active metabolite AZD1152-HQPA, which in turn has high affinity for Aurora-B and -C.
The effects of AZD1152-HQPA in cancer cells are comparable with VX-680 (89). In
preclinical models, AZD1152 significantly inhibited the growth of human tumor
xenografts. PHA-739358 is a pan-Aurora (A, B, and C) inhibitor with documented
antitumor activity in multiple tumor xenograft models, which have shown sustained
tumor growth inhibition after discontinuation of treatment. MLN8054 was the first orally
available Aurora kinase inhibitor and the first Aurora-A–selective inhibitor in clinical
trials. This compound induces mitotic accumulation and spindle defects and inhibits
proliferation in multiple human cancer cell lines (90). Tumor growth in nude mice was
inhibited after oral administration at well-tolerated doses, and the inhibition was sustained
after discontinuation of treatment. At least one phase I clinical trial has been completed
for each of the inhibitors mentioned above. Although no objective tumor responses were
observed, disease stabilization was achieved in some patients. Nonhematologic toxicities
were mild. How Aurora kinase targeting interacts with chemotherapy and radiation at the
molecular level remains to be determined, but these results are very encouraging and pave
the way for clinical studies with Aurora kinase inhibitors in the near future.
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CENTRAL HYPOTHESIS AND OBJECTIVES
Central Hypothesis
Upregulation/activation of Aurora-A by oncogenic factors and inactivation of tumor
suppressor by Aurora-A contribute to Aurora-A-induced carcinogenesis.
Objectives
To understand the molecular mechanism of Aurora-A in human cancers:
1). Aurora-A is transcriptionally regulated by E2F3;
2). Identification of tumor suppressor CHFR as an Aurora-A substrate;
3). Characterization of a novel oncogene CNTD2 as an Aurora-A interacting protein.
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CHAPTER II
IDENTIFICATION OF AURORA-A AS A DIRECT TARGET OF E2F3 DURING
G2/M CELL CYCLE PROGRESSION
Abstract
Aurora-A is a centrosome kinase and plays a pivotal role in G2/M cell cycle progression.
Expression of Aurora-A is cell cycle-dependent. Levels of Aurora-A mRNA and protein
are low in G1/S, accumulate during G2/M, and decrease rapidly after mitosis. Previous
studies have shown regulation of Aurora-A protein level during the cell cycle through
ubiquitin-proteasome pathway. However, transcriptional regulation of Aurora-A remains
largely unknown. Here, we demonstrate that E2F3 modulates Aurora-A mRNA
expression during the cell cycle. Ectopic expression of E2F3 induces Aurora-A
expression. Stable knockdown of E2F3 decreases mRNA and protein levels of Aurora-A
and delays G2/M entry. Further, E2F3 directly binds to Aurora-A promoter and
stimulates the promoter activity. Deletion and mutation analyses of Aurora-A promoter
revealed that a region located 96-bp upstream of transcription initiation site is critical for
the activation of the promoter by E2F3. In addition, expression of E2F3 considerably
correlates with the protein level of Aurora-A in human ovarian cancer examined. These
results indicate for the first time that Aurora-A is transcriptionally regulated by E2F3
during the cell cycle and that E2F3 is a causal factor for upregulation of Aurora-A in a
subset of human ovarian cancer. Thus, E2F3-Aurora-A axis could be an important target
for cancer intervention.
Key words: cell cycle, G2/M, transcription, promoter activity, ovarian cancer
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Introduction
Aurora family of serine/threonine protein kinases is evolutionally conserved from human,
Drosophila, to yeast (1,2). In mammals, the Aurora kinase family comprises three
members: Aurora-A, Aurora-B and Aurora-C. They share similar structures, with their
highly conserved catalytic domains flanked by very short C-terminal tails and N-terminal
domains of variable lengths. The N-terminal domains of the three Auroras share low
sequence conservation, which may determine selectivity during protein–protein
interactions.
As a mitotic kinase, activated Aurora-A is required for mitotic entry, centrosome
maturation and chromosome segregation (1,2). Aurora-A protein localizes to centrosomes
during interphase and to both spindle poles and spindle microtubules during early
mitosis. Ectopic expression of Aurora-A leads to an increase in centrosome number,
causes catastrophic loss or gain of chromosomes, and then results in malignant
transformation. Aurora-A kinase activity is regulated by phosphorylation,
dephosphorylation and by association with a number of proteins such as HEF1, TPX2, or
Bora (3-5).
Aurora-A is located at chromosome 20q13.2, which is commonly amplified in
various epithelial malignant tumors, including breast, colon, bladder, ovarian and
pancreatic cancers, and the levels of Aurora-A mRNA and protein are also increased in
those tumors (6-10). However, alterations of Aurora-A at mRNA and/or protein levels are
much more common than the gene amplification. Discrepancy between amplification and
overexpression rates was also reported in breast cancer, gastric cancer and ovarian cancer
(9,11,12). Therefore, Aurora-A overexpression is likely to be regulated not only by gene
amplification, but also by other mechanisms such as transcriptional activation and/or
suppression of protein degradation. Expression of Aurora-A is cell cycle regulated.
Aurora-A mRNA and protein levels begin to accumulate at G2 to M phase. After
metaphase, Aurora-A protein is rapidly degraded by the ubiquitin-mediated proteolysis,
which is promoted by the hCdh1-activated anaphase-promoting complex/cyclosome
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(APC/C). However, transcriptional regulation of Aurora-A during the cell cycle is largely
unknown.
It has been well documented that E2F family of transcription factors play
important roles in the control of expression of genes at DNA duplication as well as
further cell cycle progression (13,14). In addition, previous studies have demonstrated
that a substantial number of E2F-induced genes are normally regulated at G2 of the cell
cycle, encoding proteins known to function in mitosis (15-18). Moreover, studies in
Drosophila have provided evidence for a connection between E2F activity and the
control of mitotic activities (19). A recent report shows that both E2F1 and E2F3 are
required for cells to enter the S phase from a quiescent state, whereas only E2F3 is
necessary for the S phase in growing cells (20). The acute loss of E2F3 activity affects
the expression of genes encoding DNA replication and mitotic activities, whereas loss of
E2F1 affects a limited number of genes that are distinct from those regulated by E2F3
(21). Here we report that E2F3 upregulates Aurora-A at transcriptional level during G2
and the onset of mitosis. Among several E2F3 response elements, the region between -96
to transcriptional initiation site is responsible for E2F3 induction of Aurora-A promoter
activity. Knockdown of E2F3 reduces Aurora-A expression and delays mitotic cell cycle
progression.
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Materials and Methods
Cell Line, Culture and Transfection
HeLa, HEK293, NIH3T3 and ovarian cancer cell lines were obtained as previously
described (22,23) and cultured in Dulbecco’s modified Eagle’s medium (Sigma)
containing 10% fetal bovine serum (FBS). Cell transfection was performed with
Lipofectamine Plus Reagent (Invitrogen).
Synchronization and Cell Cycle Analyses
Cell synchronization at G1/S phase was performed using double-thymidine blocking (2).
Briefly, HeLa cells were grown in 60-mm plates and thymidine (Sigma) was added to the
culture medium at a final concentration of 2 mM for 12 h. Following two times washing
with serum free medium, cells were released in fresh culture medium containing 24 mM
2-deoxycytidine. After 9 h incubation, the second thymidine block was initiated, and
completed after 14 h. Cells were released from the block by washing in warm PBS and
replacing with complete culture medium. At different time points, cells were fixed in
70% ethanol. The fixed cells were rinsed with PBS and then stained with the propidium
iodide (PI) in a solution containing Triton X-100 and RNase A (Sigma). Cell synchrony
at various cell cycle stages was monitored by flow cytometry. To synchronize cells to Mphase, HeLa cells were incubated in DMEM medium containing 50 nM/ml nocodazole
for 14 h. Whole cell lysates and total RNA were isolated from parallel experiments for
Western and Northern blotting analyses.
Plasmids
pGL3-Aurora-A/-1486/+354, pGL3-Aurora-A/-415, pGL3-Aurora-A/-189 reporters were
kindly provided by Dr. Y. Ishigatsubo (Yokohama City University School of Medicine).
To create deletion mutants, DNA fragments corresponding to -124/+354, -96/+354 and 49/+354 were amplified by PCR using pGL3-Aurora-A/-1486 as template, respectively.
The PCR products were cloned into pGL3-basic vector at Mlu I-Bgl II sites and
confirmed by DNA sequencing. The oligonucleotide primers used were as follows: sense
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-124 5’-CGACGCGTTGGGACTGCCACAGGTCTGG-3'), -96 (5’CGACGCGTTGGCTCCACCACTTCCGG-3’), -49 (5’CGACGCGTGTGTGCGCCCTTAAACGCGAC-3’); and antisense +354 (5’GAAGATCTCTCTAGCTGTAATAAGTAAC-3’).
Aurora-A promoter mutant constructs were generated using QuikChange (Multi)
Site-Directed Mutagenesis Kit (Stratagene), including pGL3-Aurora-A/-1486mtA, pGL3Aurora-A/-1486mtB and pGL3-Aurora-A/-1486mtAB pGL3-Aurora-A/-96mtC, pGL3Aurora-A/-96mtD and pGL3-Aurora-A/-96mtCD. Primers used for mutagenesis reactions
were: mutation A, sense 5’GCGCACGCTGAAAGGGATCCAAGCCGACCGCTGCGCTATCG-3’ and antisense
5’-CGATAGCGCAGCGGTCGGCTTGGATCCCTTTCAGCGTGCGC-3’; mutation B,
sense 5’-CACTCTCTCTTGCTTTTCTATCCATCTTACTTACTGGC-3’ and antisense
5’-GCCAGTAAGTAAGATGGATAGAAAAGCAAGAGAGAGTG-3’; mutation C,
sense 5’-GGCTCCACCACTTCATGGTTCTTAGGGAGC-3’ and antisense 5’GCTCCCTAAGAACCATGAAGTGGTGGAGCC-3’; mutation D, sense 5’GAGCAAGTCGCCTGCATGCGGTGTGCGCCCTT-3’ and antisense 5’AAGGGCGCACACCGCATGCAGGCGACTTGCTC-3’.
Luciferase Assay
Cells were cultured in 24-well plates and transfected with pGL3-Aurora-A reporters, βgalactosidase and the plasmids indicated in the figure legend. The amount of DNA in
each transfection was kept constant by the addition of empty vector. After 36 h of
transfection, luciferase activity was measured using luciferase kit (Promega). The βgalactosidase activity was measured by using Galato-Light (Tropix). Transfection
efficiency was normalized by β-galactosidase expression. Luciferase activity was
expressed as relative luciferase activity. The experiments were repeated three times.
Northern and Western Blotting Analyses
Total RNA was isolated from cells using Trizol Reagent (Invitrogen). Northern blot
analysis was performed as previously described (24). Briefly, 20 µg total RNA from each
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sample was separated on 1.0% denature agarose gel. After transferring to GeneScreen
Plus Membrane (PerkinElmer) and prehybridization, the membrane was hybridized with
[32P]dCTP-labeled Aurora-A cDNA probe in Express-Hybridization Solution (Clontech).
For Western blot, equal amount of protein was separated by SDS-PAGE gel, and
electroblotted onto membranes. Following blocking in TBS-T containing 5% milk, the
membranes were hybridized with appropriate antibodies indicated in figure legend.
shRNA Lentiviral Infection
Knockdown of E2F3 was carried out by infection of HeLa cells with lentiviruses
(pLKO.1-shRNA, Sigma) expressing five different shRNAs of human E2F3, four of
which harmonize coding sequence of E2F3 and the other complements the 3’untranslation region. Briefly, HeLa cells were plated in 60-mm plates. Following culture
for 24 h and addition of polybrene, cells were infected pLKO.1-shRNA/E2F3 viruses at
multiplicity of infection (MOI) of 100. After swirling the plate, the cell-viral particle
mixture was incubated at 37°C overnight and then replaced with complete culture
medium. For transient experiments, the cells were harvested after 48 h of infection and
assayed by Western Blot. Stable knockdown of E2F3 cell lines were established by
selection with puromycin (5 µg/ml).
Chromatin Immunoprecipitation (ChIP) Assay
ChIP assay was performed essentially as previously described (25). Solubilized
chromatin was prepared from a total of 2 x 107 asynchronously growing HEK293 cells
that were transfected with E2F3. The chromatin solution containing cross-linked binding
proteins was diluted 10-fold with ChIP dilution buffer (1.1% Triton X-100, 1.2 mM
EDTA, 167 mM NaCl, 16.7 mM Tris-HCl, pH 8.1, 0.01% SDS, protease inhibitors), and
precleared with protein-A/G-agarose beads blocked with 2 µg of sheared salmon sperm
DNA and preimmune serum. The precleared chromatin solution was divided and utilized
in immunoprecipitation assays with either an anti-E2F3 antibody or an anti-actin
antibody. Following wash, the antibody-protein-DNA complex was eluted from the beads
by incubating the pellets in 1% SDS, 0.1 M NaHCO3 at room temperature for 20 min.
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The protein-DNA cross-linking was reversed, and protein and RNA were removed by
incubation with 10 µg of Proteinase K and 10 µg of RNase A at 67 °C for 6 h to
overnight. Purified DNA was subjected to PCR with primers specific for putative E2F3binding sites within the Aurora-A promoter. The sequences of the PCR primers used are
as follows: site A, sense (5’-GAATCCTGCCCAATCTACCGCTCC-3’) and antisense
(5’-GAAAAGCAAGAGAGAGTGGGACCG-3’); site B, sense (5’GCTATCGATCGGTCCCACTCTCTC-3’) and antisense (5’CTTGAGTCGCGTTTAAGGGCGCAC-3’); site C+D, sense (5’CGACGCGTTGGCTCCACCACTTCCGG-3’) and antisense (5’CCAGGAGCTCAGCCGTTAGAATTCAAAGG-3’).
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Results
Expression of the Members of E2F Family and Aurora-A during the Cell Cycle
While mRNA and protein levels of Aurora-A are elevated at G2/M phase, the underlying
molecular mechanism remains elusive. E2F family members have been shown to play a
critical role in cell cycle progression through transcriptional regulation of a number of
cell cycle-associated genes. To examine if Aurora-A is regulated by E2F family, we
compared the expression patterns of E2F family and Aurora-A proteins during the cell
cycle (Fig. 2.1A). HeLa cells were synchronized with double-thymidine blocking and
released for various time points. The cell cycle progression was monitored by flow
cytometry. Before releasing, over 60% of the total cell population was at S phase. About
6 hours, cells entered G2/M. After 16 hours, the majority of the cells were in G1 phase
(Figs. 2.1B and 2.1C). E2F1 and E2F2 protein levels were high in G1/S and decreased at
G2/M phase (Fig. 2.1A). E2F4 and E2F5 proteins distributed to the whole cell cycle.
Notably, E2F3 protein was elevated in S and maintained through G2/M phases and
decreased in G1 phase. Recent studies have shown that E2F3 but not other E2F family
members regulates the expression of genes that are involved in G2/M (21), implying that
Aurora-A could be transcriptionally regulated by E2F3.
Ectopic Expression of E2F3 Induces and Knockdown of E2F3 Decreases Aurora-A
Protein and mRNA Levels
To determine if E2F3 transcriptionally regulates Aurora-A, we transfected E2F3 into
three cell lines, which include two human epithelial cell lines Hela and A2780S, and a
mouse fibroblast NIH3T3 (Fig. 2.2A). Immunoblotting analysis showed that E2F3
upregulated Aurora-A protein expression in a dose-dependent manner (Fig. 2.2A).
Moreover, mRNA levels of Aurora-A was also induced by ectopic expression of E2F3
(Fig. 2.2B). To further demonstrate Aurora-A expression is controlled by E2F3, we
knocked down E2F3 by infection of HeLa cells with the lentiviruses (pLKO.1E2F3/shRNA) expressing 5 different E2F3 shRNAs, 4 of which are corresponding to the
coding region and the other matches the 3’-untranslated region. Fig. 2.2C showed that
35

E2F3 was considerably reduced in the cells infected with three individual shRNA as well
as their combination. After selection with puromycin, stable E2F3-knockdown pool cells
were obtained. Expression of Aurora-A was significantly reduced in these cells both at
interphase and mitosis (Fig. 2.2D).

Fig. 2.1. The correlation of expression of E2F family proteins and Aurora-A during
the cell cycle. HeLa cells were synchronized with double-thymidine block (DTB) and
released for indicated time points. A portion of cells for each time point were lysed and
immunoblotted with indicated antibodies (A). The rest were subjected to flow cytometry
(B and C).
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Fig. 2.2. E2F3 regulates Aurora A expression at protein and mRNA levels. (A and B)
Ectopic expression of E2F3 induces Aurora-A expression. HeLa, NIH3T3 and A2780S
cells were transfected with increasing amount of E2F3. Following 36 h incubation, cells
were subjected to immunoblotting analysis with indicated antibodies (A) and RT-PCR
assay for expression of Aurora-A (B). (C and D) Stable knockdown of E2F3 reduces
Aurora-A expression. HeLa cells were infected with individual lentivirus expressing 5
shRNAs targeting different regions of E2F3 and all 5 shRNAs together. After selection
with puromycin, stable knockdown clonal cells were immunoblotted with anti-E2F3 (top)
and -actin (bottom of panel C) antibodies. E2F3-stably knockdown cells were
synchronized with and without nocodazole and blotted with indicated antibodies (D).
Relative Aurora-A mRNA or protein levels were normalized to actin and quantified by
ImageJ software (NIH).
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Knockdown of E2F3 Delays G2/M Entry and Reduces Aurora-A Expression during the
Cell Cycle
Having demonstrated E2F3 transcriptional regulation of Aurora-A, we then examined the
effects of knockdown of E2F3 on G2/M progression and Aurora-A expression during the
cell cycle. pLKO.1-shRNA vector infected and E2F3 stable knockdown HeLa cells were
synchronized by double-thymidine block. Flow cytometry analysis revealed that cells
with knockdown of E2F3 delays to enter G2/M phase as compared to the pLKO.1 vectorinfected cells (Fig. 2.3A). In consistence with cell cycle change, elevation of Aurora-A
mRNA and protein levels was approximately 2 or 3 h delayed by knockdown of E2F3.
Moreover, the mRNA and protein levels of Aurora-A at G2/M phase were also reduced
in E2F3-knockdown cells as compared to control shRNA-treated cells (Figs. 2.3B and
2.3C). However, Aurora-A protein underwent degradation at late M phase in both cell
lines (Fig. 2.3C). These data further suggest that Aurora-A is transcriptionally regulated
by E2F3 during the cell cycle.
E2F3 Binds to and Transactivates Aurora-A Promoter during G2/M Phase
We next examined whether the Aurora-A promoter is transactivated by E2F3. HeLa cells
were transfected with pGL3-Aurora-A/-1486/+354-Luc reporter and increasing amounts
of E2F3. Luciferase reporter assay revealed that Aurora-A promoter activity was induced
by E2F3 in a dose-dependent manner (Fig. 2.4A). Moreover, basal level of Aurora-A
promoter activity, especially at mitosis, was reduced in E2F3-knockdown cells as
compared to pLKO.1 vector-infected HeLa cells (Fig. 2.4B).
Sequence analysis showed 4 putative E2F-binding elements
[TT(C/G)GCGC(C/G)] within the promoter (Fig. 2.4C). To define the response region(s)
of the promoter to E2F3, we created a series of deletion mutants of Aurora-A promoter.
Reporter assay showed that a mutant with deletion from -1486 to -415 significantly
deceased E2F3-induced promoter activity while it still contains all 4 putative E2Fbinding elements, implying that this region is of transactivation function. Moreover, the
deletion of 2 distal E2F-binding sites (i.e., from -1486 to -189; A and B) further reduced
the promoter activity. However, promoter activity of the mutants with additional deletion
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of either from -189 to -124 or from -189 to -96, both of which retain the 2 E2F-response
elements (C and D) proximal to the transcriptional starting site, was significantly induced
by E2F3. The promoter activity was completely abrogated by further deletion of the
proximal E2F-response elements (Fig. 2.4C). These results suggest that the region from 189 to -96 contains a repression element(s) and that the all four E2F-binding sites are
response to E2F3. However, the two binding elements proximal to the transcriptional
start site are sufficient for E2F3 transactivation of the Aurora-A promoter.

Fig. 2.3. Knockdown of E2F3 results in mitotic cell entry delay and decreased
Aurora-A expression during the cell cycle. Control shRNA and stable E2F3-shRNA
infected HeLa cells were synchronized with double-thymidine block and released for
indicated time points. Cells were analyzed by flow cytometry (A), Northern (B) and
Western (C) blotting with indicated probe and antibodies.
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Fig. 2.4. Aurora-A promoter is regulated by E2F3. (A) Ectopic expression of E2F3
induces Aurora-A promoter activity. NIH3T3 cells were transiently transfected with
indicated plasmids. Following 48 h incubation, luciferase activity was measured and
normalized to β-gal. Results are the mean ± SEM of three independent experiments
performed in triplicate (top). Bottom panel shows expression of transfected E2F3. (B)
Knockdown of E2F3 reduces basal level of Aurora-A promoter activity. Aurora-A-Luc
and β-gal were introduced into pLKO.1 control shRNA- and E2F3-shRNA-infected HeLa
cells. After 36h incubation, cells were treated with and without nocodazole for 12 h and
then subjected to luciferase assay. (C) Deletion mapping of E2F3 response elements in
Aurora-A promoter. NIH3T3 cells were transfected with indicated Aurora-A deletion
mutants and different amounts of E2F3 plasmid. E2F3 binding sites were labeled as “A –
D”. Luciferase assay was performed after 36 h of transfection.
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To determine whether E2F3 could directly bind to the E2F-binding sites of the
Aurora-A promoter in vivo and to further define the E2F3 response elements in the
promoter, we carried out ChIP assay, which detects specific genomic DNA sequences
that are associated with a particular transcription factors in intact cells. HeLa cells were
transfected with wild type E2F3. Following 36 h incubation, unsynchronized cells were
immunoprecipitated with an anti-E2F3 antibody. The E2F3 bound chromatin was
subjected to PCR using 3 pairs of oligonucleotide primers that amplify regions spanning
each distal and 2 proximal E2F3-binding sites within the Aurora-A promoter because 2
proximal E2F-binding sites are so close that could not be separated by ChIP assay. As
shown in Figs. 2.5A and 2.5B, the anti-E2F3 antibody pulled down all E2F-binding sites.
In contrast, immunoprecipitation with an irrelevant antibody (e.g. anti-Actin) resulted in
the absence of bands in these sites. These results indicate that E2F3 directly binds to the
Aurora-A promoter. By mutation of individual or combinational E2F3 binding sites (CG
AT) in Aurora-A promoter, we further demonstrated that the 2 E2F-response elements
proximal to transcriptional start site are required for E2F3 transactivation of the Aurora-A
promoter (Figs. 2.5A and 2.5B).
Since mRNA and protein levels of Aurora-A are low at G1 and gradually increase
during G2/M phase, we next examined if E2F3 binding to and activation of the Aurora-A
promoter is cell cycle dependent. HeLa cells were transfected with pGL3-Aurora-A or
pGL3-vector. Following synchronization with double-thymidine block, ChIP and
luciferase reporter assays were performed at different phases of the cell cycle. Fig. 2.5C
shows that E2F3 barely interacts with Aurora-A promoter during G1/S phase. The
binding and transactivation activities of E2F3 toward the Aurora-A promoter were
significantly increased upon cell entering G2/M phase. These data further support the
notion that E2F3 plays a pivotal role in Aurora-A expression during G2/M phase.
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Fig. 2.5. E2F3 binds to Aurora-A promoter in a cell cycle dependent manner. (A and
B) E2F3 interacts with Aurora-A promoter in vivo. ChIP assay was performed as
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described in Materials and Methods with unsynchronized HeLa cells (left panels). E2F3
binding sites C and D are too close to separate by ChIP assay. Luciferase assay was
performed with Aurora-A-Luc reporter plasmids containing E2F3-binding site mutation
(right panels). (C) E2F3 binds to Aurora-A promoter during G2/M phase. HeLa cells
were synchronized with double-thymidine block and released for indicated times. Cell
cycle was monitored with flow cytometry (top) and ChIP assay was performed for each
time point (panel 2). Aurora-A RNA levels (pane 3) and promoter activity (bottom) are
correlated with E2F3 binding to Aurora-A promoter.
Correlation of Expression of E2F3 and Aurora A
To further demonstrate E2F3 regulation of Aurora-A, we transfected GFP-E2F3 into
HeLa cells. After 48 h of transfection, cells were immunostained with anti-Aurora-A
antibody. As shown in Fig. 2.6, cells expressing GFP-E2F3 exhibited higher density and
clearer centrosome than the cells that did not, further indicating E2F3 upregulation of
Aurora-A.

Fig. 2.6. Expression of E2F3 increases Aurora-A density in centrosome. HeLa cells
were transfected with GFP-E2F3 and immunostained with anti-Aurora-A antibody. Two
cells are shown in the picture (arrows), one cell expresses E2F3 (green) and the other one
does not.
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We and others have previously shown amplification and overexpression of
Aurora-A in ovarian cancers (9,26). However, the frequency of elevated Aurora-A
protein and/or mRNA is much higher than its change at DNA level (e.g. ~l5%),
suggesting the mechanism of activating transcription and/or translation of Aurora-A in
ovarian cancer cells. While overexpression of E2F3 has been detected in different tumors
(27-29), the E2F3 status in ovarian cancer has not been well documented. Thus, we
reasoned that E2F3 could be elevated in ovarian cancer and might be a causal factor of
upregulation of Aurora-A. To this end, we examined protein levels of E2F3 and AuroraA in human ovarian cancers. Immunoblotting analyses were performed in total 8 ovarian
cancer cell lines and 72 microdissected ovarian tumor specimens (Figs. 2.7A and 2.7B).
Elevated levels of E2F3 and Aurora-A were detected in 43 of 72 (60%) and 41 of 72
(57%) primary tumors, respectively, as well as majority of ovarian cancer cell lines
examined. Notably, 78% (32/41) of tumors with high levels of Aurora-A overexpress
E2F3 (Fig. 2.7C). Co-upregulation of E2F3 and Aurora-A seems to be predominantly
observed in serous ovarian carcinomas and clear cell tumors although the number of
cases is relatively small (Fig. 2.7D). These data indicate that in a large subset of ovarian
tumors elevated Aurora-A might result from expression of high level of E2F3 and further
support the findings of biochemical and functional links between E2F3 and Aurora-A.
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Fig. 2.7. Overexpression of E2F3 correlates with Aurora-A level in human ovarian
tumors. (A and B) Western blot analysis. Representative ovarian cancer cell lines (A)
tumor and normal ovarian tissue (B) lysates were analyzed by Western blot with
indicated antibodies. Intensity of E2F3 and Aurora-A were quantified via ImageJ
software. The overexpression of E2F3 and Aurora-A in tumor samples was scored based
on the average values of the normal tissues from three independent experiments.
Table 2. Summary of expression of E2F3 and Aurora-A in ovarian cancer.
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Discussion
In this report, we investigated the transcriptional regulation of Aurora-A by E2F3.
Ectopic expression of E2F3 induced mRNA and protein levels of Aurora-A whereas
knockdown of E2F3 decreased Aurora-A expression and resulted in mitotic cell cycle
delay, which resembles the mitotic arrest phenotypes in Aurora-A siRNA treated cells
(4). Notably, chromatin immunoprecipitation revealed that E2F3 bound to Aurora-A
promoter in vivo and the interaction is cell-cycle dependent, i.e., primarily occurred
during G2/M phase. Moreover, co-overexpression of Aurora-A and E2F3 was frequently
detected in ovarian cancer. These findings are important for several reasons. First, they
provide a mechanistic understanding of transcriptional regulation of the Aurora-A
expression during the cell cycle. Second, a direct link between Aurora-A and the E2F3
has now been established. Finally, this is the first demonstration of co-alteration of E2F3
and Aurora-A in human ovarian cancer and elevated E2F3 could be a causal factor for
deregulation of Aurora-A in this disease.
In mammalian cells, E2F family is composed of 10 distinct gene products
encoded by eight independent loci that can be divided into three subfamilies based on
their sequence homology – the E2F1–3 genes, the E2F4 and 5 genes and the E2F6–8
genes. The E2F1–3 genes have been shown to be tightly regulated during the cell cycle,
whereas the E2F4–8 genes are constitutively expressed. Functionally, E2F1–3 act as
positive regulators of transcription whose accumulation is tightly regulated and in most
cell types correlates with increased cell proliferation (30-32), whereas E2F4 and E2F5,
when bound to p130 or Rb, act as transcriptional repressors (33). The E2F6–8 proteins
appear to function as Rb-independent transcriptional repressors (34,35). In addition, the
E2F3 locus expresses two distinct transcripts, full-length E2F3a and N-terminal-truncated
E2F3b transcribed from an intronic promoter within the E2F3 locus (36). E2F3a
expression is cell cycle regulated whereas E2F3b is expressed equivalently in quiescent
and proliferating cells, and may have an opposing role to E2F3a in cell cycle control.
Accumulated evidence shows that E2F3 (e.g. E2F3a) regulates S and G2/M cell cycle
progression (15,16). Gene expression microarray analyses have revealed that E2F3
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regulates many of the DNA replication, mitotic and cell cycle regulatory genes (15,21). A
previous report has shown that E2F3 regulates cyclin B1, cyclin A2 and cdc2
transcription (18). We demonstrated, in the present study, that E2F3 directly binds to
Aurora-A promoter and tightly regulates Aurora-A expression during the G2/M phase.
Previous studies have shown that Aurora-A is transcriptionally regulated by
E4TF1, a member of the Ets family, and GABP, the Ets-related transcription factor
GABP (37,38). E4TF1 and GABP bind to the same DNA-binding motif (CTTCCGG; -85
to -79) of the human Aurora-A promoter to induce Aurora-A promoter activity and
transcription. The transactivation of Aurora-A by GABP is regulated through interaction
with TRAP220/MED1, an evolutionarily conserved multisubunit coactivator that plays a
central role in regulating transcription from protein-encoding genes (37,38). Tanaka et al.
cloned human Aurora-A promoter and identified 2 E2F binding elements which
correspond to the binging sites A and B in Fig. 2.4C. The findings presented here show
that while E2F3 binds to these 2 sites, their mutations still respond to E2F3 (Fig. 2.5A).
This led us to identify 2 more E2F binding motifs proximate to transcriptional start site
(Fig. 2.4C). ChIP and reporter assays show that they are required for the transcriptional
activation of Aurora-A gene by E2F3 (Figs. 2.5 B and 2.5C).
Previous reports have demonstrated that E2F3 is frequently overexpressed in a
variety of types of human malignancy and whose alteration is associated with late stage
and high grade tumors. However, alterations of E2F3 in human ovarian cancer have not
been well documented while a gene expression array study shows upregulation of E2F3
in ovarian tumor (39). Previously, we have shown frequent overexpression of Aurora-A
in ovarian cancer. In the present study, we demonstrated frequent co-existence of
elevated levels of E2F3 and Aurora-A in human primary ovarian carcinoma. Strong
association of elevated E2F3 expression and Aurora-A in ovarian tumors underscored the
clinical significance of the E2F3-Aurora-A signaling axis. It is very likely that elevated
E2F3 is one of the major transcriptional factors that contribute to upregulation of AuroraA in other human primary tumors. As described above, E4TF1 and GABP are known
transcriptional regulators of Aurora-A (37,38), however, their role in Aurora-A induction
in human cancer are unclear.
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Importance of Aurora-A and E2F3 in oncogenesis has been well established by
their alterations in human neoplasms and their capacity to induce cell transformation (2729,40). Based on our current observations, we believe that Aurora-A, as a mitotic E2F3
target gene, could mediate E2F3 oncogenic function. Pharmacological agents that inhibit
E2F3 or its downstream mediator Aurora-A may lead to inhibition of tumor development
underscoring the significance of the E2F3-Aurora-A axis as an attractive target for cancer
therapy.
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CHAPTER III
AURORA-A FEEDBACK REGULATION OF CHFR, A TUMOR SUPPRESSOR
FREQUENTLY DOWNREGULATED IN OVARIAN CANCER
Abstract
CHFR is a tumor suppressor gene which encodes a forkhead-associated (FHA) and ringfinger (RF) domains containing protein and plays an important role in G2/M cell cycle
checkpoint. Previous studies show that CHFR exerts tumor suppressor function via its E3
ligase activity by targeting Aurora-A and polo-like kinase degradation. Hypermethylation
and mutation of CHFR have been detected in human cancer from different organs
including stomach, breast, colon and lung. However, molecule(s) that regulate CHFR
function and alteration of CHFR in human ovarian cancer remain largely unknown. Here
we demonstrate that Aurora-A phosphorylates CHFR at serine-218 and serine-337 in
vitro and in vivo. Phosphorylated CHFR reduces its E3 activity and tumor suppressor
function. Further, frequent downregulation of CHFR was detected in human ovarian
cancer cell lines and primary tumors. Expression of the CHFR could be restored by
treatment with methyltransferase inhibitor 5-aza-2'-deoxycytidine and histone deacetylase
inhibitor TSA. Three of 4 cell lines and 9 of 17 tumors with downregulation of CHFR
exhibited higher levels of Aurora-A, supporting the notion that CHFR is an E3 ligase of
Aurora-A. These findings indicate that CHFR is a substrate of Aurora-A and that
epigenetic inactivation of CHFR is a recurrent event in ovarian cancer and could play a
pivotal role in ovarian oncogenesis.
Key words: tumor suppressor, E3 ligase, hypermethylation, phosphorylation, ovarian
cancer
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Introduction
The segregation of chromosomes at mitosis involves several processes, including
chromosome condensation in prophase, chromosomal alignment on the spindle in
metaphase, and sister-chromatids separation in anaphase (1-3). CHFR (checkpoint with
forkhead and ring finger) has been discovered as a prophase checkpoint protein.
Activation of CHFR delays chromosome condensation and nuclear envelope breakdown
in response to mitosis stress induced by taxol or nocodazole (4). The CHFR protein
contains an N-terminal forkhead-associated (FHA) domain, a central ring finger (RF)
region, and a C-terminal cysteine-rich (CR) motif. The FHA domain is conserved in
several checkpoint genes, which plays a role in recognizing phosphorylated proteins.
Deletion of the FHA domain has been shown to attenuate CHFR function; the CR domain
is also required for the checkpoint function (4). The RF domain is required for CHFR
ubiquitin ligase activity. It has been shown that CHFR mediates the degradation of pololike kinase 1(PLK1), Aurora-A and CHFR itself. Ubiquitination of PLK1 by CHFR
delays the activation of Cdc25C and the inactivation of Wee1, leading to delay of Cdc2
activation, which provides a molecular mechanism that CHFR executes checkpoint
function by ubiquitin-dependent proteolysis (5). However, another study suggests that
CHFR delays cells in early prophase by inhibiting entry of cyclin B1 in the nucleus (6).
CHFR localizes to chromosome 12q24.33, where is frequently deleted in human
cancers (7-9). The frequent inactivation of CHFR which caused by DNA methylation or
mutation has been reported in human primary tumor and cancer cell lines of lung, colon,
esophagus, gastric, brain, bone and breast (10-14). CHFR-deficient mice are cancer-prone
and develop spontaneous tumors (15).
Aurora-A kinase is required for mitotic entry, centrosome maturation and
chromosome segregation (16,17). Aurora-A expression and kinase activity are cell cycle
regulated. Aurora-A mRNA and protein levels begin to accumulate at G2/M transition.
After executing its mitotic kinase function through metaphase, Aurora-A protein is
rapidly degraded by hCdh1-activated anaphase-promoting complex/cyclosome (APC/C)
(18). The precise timing of activation and degradation is the key feature of Aurora-A
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regulation. A previous report has demonstrated that CHFR serves as the E3 ligase for
Aurora-A proteasome degradation (15). In the present study, we show that CHFR is a
substrate of Aurora-A and is downregulated in ovarian cancer. Aurora-A phosphorylates
CHFR leading to inhibition of its E3 ligase activity. We previous showed frequent
upregulation of Aurora-A in human ovarian cancer and demonstrated in this report
inverse correlation of Aurora-A and CHFR expression in this malignancy. Thus, these
results uncover a feedback regulation loop between Aurora-A and CHFR and suggest
potential importance of CHFR-Aurora-A axis in ovarian carcinogenesis.
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Materials and Methods
Cell Lines, Transfection and Treatment
The human epithelial ovarian cancer cell lines were cultured in appropriate mediums
supplemented with 10% fetal bovine serum: OV3, OV5, OV8, A2780S, IGROV, OV90
and C13 were grown in RPMI 1640 medium; OV2 was cultured in 50:50 medium
M199:MCDB105; RMUG-S was grown in F-12 medium; UTOV1, UTOV2, UTOV3A
and UTOV4 were cultured in DMEM. All the media were supplemented with 2 mM Lglutamine, 1% nonessential amino acids, 100 IU/ml penicillin and 100 IU/ml
streptomycin. Human embryonic kidney (HEK) 293 cells were cultured in DMEM
containing 10% FBS. Cells were seeded in 60-mm Petri dishes at a density of 0.5 × 106
cells/dish. Cells were grown overnight to reach log growth phase before transfection.
Transfection was performed using LipofectAMINE 2000 (Invitrogen).
To restore endogenous CHFR expression, the cells were treated methyltransferase
inhibitor 5-aza-2'-deoxycytidine (5-aza) at concentration of 5 µM for 4 days and HDAC
inhibitor Trichostatin-A (TSA, 100 ng/ml) for last 24 hours. Cycloheximide (CHX) was
used to block protein synthesis at a concentration of 50 µg/ml. Proteasome inhibitor
MG132 was administered to cells at 10µM for 6 hours in ubiquitination assay.
Plasmids
pcDNA3-myc-CHFR was kindly provided by Dr. Junjie Chen. Different truncated forms
of GST-CHFR were created by PCR amplification using pcDNA3-myc-CHFR as a
template. The PCR products were digested by BamHI and XhoI and cloned into
pGEX4T-1 vector. The accuracy of resulting constructs was confirmed by DNA
sequencing. The oligonucleotide primers used were as follows: CHFR1 (sense), 5’CGCGGATCCAAGCTTATGGAGCGGCCCGAGGAAGGCAAG-3’; CHFR110
(sense), 5’-CGCGGATCCAAGCTTAATGAACCGGAACACAACGTGGCA-3’;
CHFR124 (antisense), 5’TGCTCTAGCCTCGAGACTTAAAGATTCATAGAGGTATGC-3’; CHFR279 (sense),
5’-CGCGGATCCAAGCTTAGAAATGCCCAAACCGTCCACGAG-3’; CHFR281
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(antisense), 5’-TGCTCTAGCCTCGAGGGCATTTCTACGCGGTTGTGCGAC-3’;
CHFR376 (antisense), 5’TGCTCTAGCCTCGAGCACATCTTCTTCACTGCGACTCTT-3’.
CHFR mutant plasmids were generated by QuikChange (Multi) Site-Directed
Mutagenesis Kit (Stratagene), including pCDNA3-myc-CHFR/S218A, pCDNA3-mycCHFR/S337A, pCDNA3-myc-CHFR/S218S337A; and GST-CHFR-C2/S218A, GSTCHFR-C2/S337A, GST-CHFR-C2/S218S337A. Primers used for mutagenesis reactions
were: CHFR-S218A-F, 5’-CCTAAAGGAGCTGGTCCCTCTGTG-3’; CHFR-S218A-R:
5’-CACAGAGGGACCAGCTCCTTTAGG-3’; CHFR-S337A-F, 5’ATGGAGCGCTCGGCCCTGTGTCCT-3’; CHFR-S337A-R, 5’AGGACACAGGGCCGAGCGCTCCAT-3’.
RT-PCR
Total RNA was isolated from cells or tissues using Trizol Reagent (Invitrogen). 1-2 µg
RNA was reverse transcripted by M-MLV reverse transcriptase (Promega) at 37°C for
1.5 hour. The sequential PCR reaction to amplify CHFR from the cDNA was carried out
using Taq polymerase (Promega) with 30 cycles of denaturation 30 seconds at 95°C;
annealing 30 seconds at 60°C; and extension 60 seconds at 72°C. The primers used for
PCR were: CHFR-RT-F, 5’-GGCGAGAGCGTTCTCCAGTTG-3’; CHFR-RT-R, 5’GCATGTCAGCGTCTCCTCCATCTTG-3’.
Western Blotting Analysis and Immunoprecipitation
Western blotting analysis was performed as previously described (19). Briefly, cells and
tumor tissues were lysed in RIPA buffer (50 mM NaCl, 0.5% (w/v) DOC, 50 mM TrisHCl (pH 8.0), 1% (v/v) NP-40, 0.1% (w/v) SDS, 1µg/ml aprotinin, 1µg/ml leupeptin,
0.5mM Na3VO4 and 1mM PMSF). Equal amounts of proteins were separated in SDSpolyacrylamide gel and electroblotted onto Nitrocellulose (Amersham) membranes.
Following blocking in TBS-T containing 5% milk, the membranes were hybridized with
appropriate antibodies indicated in figure legend. Detection of antigen-bond antibody was
carried out using ECL Western Blotting Detection System (Amersham).
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For immunoprecipitation (IP), cells were lysed in TNEN buffer containing 50 mM
Tris-HCl (pH 7.5), 150 mM NaCl, 2 mM EDTA, 0.5% (v/v) NP40, 0-0.3% (v/v) Triton
X-100, protease and phosphatase inhibitors (1µg/ml aprotinin, 1µg/ml leupeptin, 0.5mM
Na3VO4 and 1mM PMSF). The lysates were precleared with 25µl protein A-protein G
(2:1) agarose beads at 4°C for 30 min. Following removal of the beads by centrifugation,
the lysates were incubated with 30µl antibody conjugate protein A:G (2:1) agarose beads
at 4°C for 4 hours. The beads were washed 3 times with lysis buffer and subjected to
immunoblotting analysis with the antibodies indicated in figure legend.
In vivo [32P] Pi Labeling
HEK293 cells were co-transfected with myc-CHFR and HA-Aurora-A or pcDNA3. After
24 hours incubation, cells was serum starved for overnight and then incubated with
phosphate-free and serum-free medium for 2 hours. [32P] Pi was added to the same
medium at final concentration of 0.5 mCi/ml. Following 4 hours incubation, cells were
lysed and subjected to immunoprecipitation with anti-Myc antibody. The
immunoprecipitates were separated by SDS-PAGE and transferred to membranes.
Phosphorylated CHFR band was examined by autoradiography. The expression of
transfected CHFR and Aurora-A was detected with anti-Myc and -HA antibodies,
respectively.
In vitro Aurora-A Kinase Assay
Aurora-A kinase assay was performed as previously described (20). Briefly, reactions
were carried out in a kinase buffer in the presence of 10 µCi of [γ-32P] ATP (Perkin
Elmer Life Sciences). Recombinant Histone H3 or purified GST-CHFR protein was used
as substrate. After incubation at 30°C for 30 min, the reaction was stopped by adding
protein loading buffer. The proteins were separated by SDS-PAGE, and the amounts of
incorporated radioactivity were determined by autoradiography.
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2-Dimentional Phosphopeptide Mapping and Edman Degradation
Following in vitro kinase assay, Aurora-A-phosphorylated CHFR was extracted from the
SDS-polyacrylamide gel by cutting the protein band and incubating in a buffer containing
50 mM ammonium bicarbonate, 1% 2-mercaptoethanol, and 0.2% SDS for at least 90
min duplicated at 37°C. After chloroform precipitation and oxidation with performic acid,
the sample was evaporated and resuspended by ammonium bicarbonate. The protein was
digested with 10 ng of L-1-tosylamido-2-phenylethyl chloromethyl ketone-treated trypsin
at 37 °C for overnight, followed by an additional overnight incubation at 37°C in the
presence of a fresh 10 ng of the same proteinase. The trypsin digests were washed for 4
times, lyophilized, and resuspended in deionized water.
Phosphopeptides of CHFR were resolved at the first-dimension by electrophoresis
on the cellulose layer of TLC plate for 30 min at 1.0 kV in 88% formic acid/glacial acetic
acid/water (1:3.1:35.9; pH 1.9) and 4.7 (n-butanol:pyridine:glacial acetic acid:water =
2:1:1:36), and then for 20 min in a buffer pH 8.9 (10 g ammonium carbonate in 1 liter
water) using the HTLE-7000 system. The phosphopeptides were further separated at
second-dimension by chromatography in Phosphochromatography buffer (nbutanol:pyridine:glacial acetic acid:water = 5:3.3:1:4). The phosphopeptides were
visualized by autoradiography.
For phosphoamino acid analysis, the phosphopeptides were recovered from the
TLC plates and hydrolyzed in 6N HCl at 110°C for 60 min. Following acid hydrolysis,
phosphoamino acids were separated by two-dimensional electrophoresis on TLC plates.
The electrophoresis was carried out for 20 min at 1.5 kV in pH 1.9 buffer for the first
dimension and for 16 min at 1.3 kV in pH 3.5 buffer (pyridine:glacial acetic acid:water =
1:10:189) for the second dimension. Phosphoamino acid standards, which were mixed
with each sample, were visualized by staining with 0.25% w/v ninhydrin in acetone.
For Edman degradation, the phosphopeptides were eluted from the cellulose layer
of the TLC plates by incubation in deionized water for 30 min at room temperature;
second elution may be applied if necessary. The purified phosphopeptides were subjected
to manual Edman degradation to determine at which position the phosphorylated amino
acid was present in the peptide. At pH 8.0 to 9.0, phenylisothiocyanate reacted with the
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free amino group of the most amino-terminal amino acid to form a corresponding
phenylthiocarbamyl (PTC) peptide. During each cycle of Edman degradation, treatment
of trifluoroacetic acid (TFA) resulted in the cleavage and release of the derivatized
amino-terminal amino acid, and a sample from the reaction mixture was withdrawn. If a
phosphoserine or phosphothreonine residue is present, a β-elimination during the
cyclization released free phosphate. The free phosphate was separated from the peptide
by electrophoresis, and the phosphoamino acid was determined.
In vivo Ubiquitination Assay
The cell ubiquitination assay was carried out as previously described (21). HEK293 cells
were transfected with combinations of His6-Ubiquitin, HA-PLK1, myc-CHFR and HAAurora-A using calcium phosphate. After 36 h of transfection, cells were collected into
two aliquots, one of which was used for Western blot analysis to confirm expression of
transfected plasmids and the other was subjected to purification of His6-tagged protein
using Ni2+-nitrilotriacetic acid (NTA) conjugated agarose beads (Qiagen). Briefly, the
cell pellet was lysed in buffer A (6 M guanidinium-HCl, 0.1 M Na2HPO4/NaH2PO4 [pH
8.0], 0.01 M Tris-HCl [pH 8.0], 10 mM imidazole, 10 mM β-mercaptoethanol) and
incubated with Ni2+-NTA beads for 6 hours at room temperature. The beads were
sequentially washed with buffer A, buffer B [8 M urea, 0.1 M Na2PO4/NaH2PO4 [pH
8.0], 0.01 M Tris-HCl (pH 8.0), 10 mM imidazole, 10 mM β-mercaptoethanol], buffer C
[8 M urea, 0.1 M Na2PO4/NaH2PO4 (pH 6.3), 0.01 M Tris-HCl (pH 6.3), 10 mM
imidazole, 10 mM β-mercaptoethanol], 0.2% Triton X-100, and then buffer C. The beads
bound proteins were eluted with buffer D [200 mM imidazole, 0.15 M Tris-HCl (pH 6.7),
30% glycerol, 0.72 M β-mercaptoethanol, 5% SDS] at room temperature. The eluted
proteins were analyzed with Western blot in the presence of ubiquitin-conjugated PLK1
using anti-HA antibody.
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Results
Downregulation of CHFR in Human Ovarian Cancer and the Correlation between
Expression of CHFR and Aurora-A
While epigenetic inactivation of CHFR has been observed in various types of human
malignancy (22-26), its alteration in ovarian cancer remains elusive. Since CHFR resides
in chromosome 12q24 region, which is frequently deleted in ovarian cancer (27), we
examined expression of CHFR in both ovarian cancer cell lines and primary tumors by
semi-quantitative RT-PCR. Fig. 3.1A shows that CHFR was downregulated in 8 of 17
ovarian cancer cell lines and 17 of 30 primary ovarian tumors examined. Undetectable
CHFR was observed in 4 cell lines and 9 primary tumors. To determine if DNA
methylation is responsible for CHFR downregulation in ovarian cancer, we treated 4
ovarian cancer cell lines, which do not express CHFR, with combined 5-aza
(methyltransferase inhibitor) and TSA (HDAC inhibitor). CHFR expression was restored
in C13 cells (Fig. 3.1B) but not the other 3 cell lines (data not shown), suggesting that
DNA methylation is not the only mechanism for downregulation of CHFR. Nevertheless,
these results indicate that deregulation of CHFR is a recurrent event in human ovarian
cancer.
We and others have previously shown amplification and overexpression of
Aurora-A in 15% and 50% ovarian cancers, respectively (28), suggesting that
deregulation of Aurora-A at transcriptional or/and translational levels occurs in a large
fraction of tumors. Since CHFR is an E3 ligase of Aurora-A (15), downregulation of
CHFR could be a causal factor for upregulation of Aurora-A. By comparing expression
levels of CHFR and Aurora-A, we found an inverse correlation between Aurora-A and
CHFR expression in a subset of ovarian cancer (Fig. 3.1C). For instance, C13 and SW626
cells do not express CHFR, but have high levels of Aurora-A, whereas SKOV3 and
OV90 express CHFR but not Aurora-A (Fig. 3.1C). However, it is noted that a subset of
ovarian cancers exhibit high levels of both Aurora-A and CHFR, suggesting a feedback
regulation between Aurora-A and CHFR.
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Fig. 3.1. Frequent downregulation of CHFR in ovarian cancer. (A) RT-PCR analysis
of CHFR mRNA levels in ovarian cancer cell lines and primary ovarian tumors. Total
RNA was isolated and subjected to RT-PCR analysis for expression of CHFR (top) and
β-actin (bottom). (B) Restoration of CHFR in C13 cells by demethylation. C-13 and OV3
cells were treated with 5-Aza for 72 hours and together with TSA for another 24 hours.
(C) Correlation between expression of Aurora-A and CHFR. Indicated ovarian cancer
cells were immunoblotted with anti-Aurora-A (top panel) and β-actin (panel 2) antibodies.
RNAs from these cells were subjected to RT-PCR analysis for expression of CHFR
(panel 3) and β-actin control (bottom panel).
Aurora-A Phosphorylates CHFR in vivo and in vitro
To determine if Aurora-A phosphorylates CHFR, we carried out in vivo labeling
experiment. HEK293 cells were co-transfected with Myc-CHFR together with/without
HA-Aurora-A. Following 48 h incubation, cells were labeled with orthophosphate [32P]
Pi and immunoprecipitated with anti-Myc antibody. The immunoprecipitated Myc-CHFR
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was separated by SDS-PAGE and the phosphorylated CHFR protein was revealed by
autoradiography. Fig. 3.2A shows that phosphorylation level of CHFR was significantly
increased in cells cotransfected with Aurora-A/CHFR as compared to cells treated with
CHFR alone. We next carried out in vitro kinase assay. Immunoprecipitated CHFR was
incubated with or without recombinant Aurora-A protein (Upstate). As shown in Fig.
3.2B, CHFR phosphorylation was detected only in the presence of Aurora-A kinase.
These findings demonstrate that CHFR is phosphorylated by Aurora-A in vitro and in
vivo.

Fig. 3.2. CHFR is phosphorylated by Aurora-A. (A) In vivo labeling. HEK293 cells
were transfected with myc-CHFR and HA-Aurora-A or vector, labeled by [32P] Pi and
immunoprecipitated with anti-Myc antibody. The immunoprecipitates were separated in
SDS-PAGE and the phosphorylated CHFR was revealed by autoradiography (top panel).
Expression of Aurora-A and CHFR as well as even loading were confirmed by Western
blot analysis with anti-HA (panel 2), -Myc (panel 3) and -actin (bottom panel) antibodies.
(B) In vitro kinase assay. Myc-CHFR was introduced to HEK293 cells and
immunoprecipitated with anti-myc antibody. The immunoprecipitated Myc-CHFR was
incubated with recombinant Aurora-A protein in kinase buffer for 30 min. The reactions
were stopped by protein loading buffer and resolved by SDS-PAGE (top panel). Bottom
panel is the gel stained with Coomassie blue. Above phosphorylation levels of CHFR
were quantified by ImageJ.
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Mapping Phosphorylation Sites of CHFR by Aurora-A
To define the Aurora-A phosphorylation site(s) of CHFR, we generated a series of
glutathione S-transferase (GST)-CHFR truncated fusion proteins (Fig. 3.3A). In vitro
kinase assay revealed that CHFR fragments C2 (aa1-376) and C4 (aa110-376) were
highly phosphorylated by Aurora-A; but minimal or no phosphorylation was observed in
C1 (aa1-124), C3 (aa110-281) and C5 (aa279-376). This indicates that Aurora-A
phosphorylation of CHFR site(s) must reside in a region between aa110 to aa376.
To map the phosphorylation sites of CHFR by Aurora-A, we performed 2Dimensional Phosphopeptide Mapping analysis. In vitro kinase assay was carried out by
incubation of GST-CHFR-C2 protein with recombinant Aurora-A. The phosphorylated
GST-CHFR-C2 was extracted from SDS-PAGE gel. After digestion with trypsin, which
cleaves the peptides after R/K, the phosphopeptides were separated on TLC plates. As
shown in Fig. 3.3B, we identified 2 major phosphopeptides A and B. To determine
whether the phosphorylated residue is serine or threonine, we performed Phosphoamino
Acid Analysis. The phosphopeptides were recovered from the TLC plates. Following
acid hydrolysis, phosphoamino acids were separated by two-dimensional thin-layer
electrophoresis on TLC plates. The plates were dried in 80°C for 30 minutes, sprayed
with ninhydrin in acetone and reheated for 5 minutes to visualize the phosphoamino acid
standards. Following autoradiography, align the film with the plate and both the residues
were identified to be serine (Fig. 3.3C). The phosphopeptides isolated from TLC plates
were subjected to manual Edman degradation to determine the position of the
phosphorylated amino acid in the peptide. Basically, the labeled peptides were cleaved
one by one from the very amino-terminal of the peptide without disrupting the peptide
bonds between other residues. The [32P]-labeled phosphate group was released where the
phospho-residue was cleaved, and form a separate spot from the peptide and closer to the
anode, because the phosphate is smaller and negatively charged. As shown in Fig. 3.3D,
both the phosphopeptides released the phosphate at the second cycle. Judging from the
amino acid sequence of CHFR-C2, the endoproteinase trypsin-digested peptides that
contain serine or threonine at position 2 are serine-218 and serine-337, respectively (Fig.
3.3D).
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Fig. 3.3. Define Aurora-A phosphorylation sites of CHFR. (A) Different CHFR
fragments were fused to GST (top). In vitro Aurora-A kinase assay was carried out by
incubation of GST-CHFR fusion proteins with recombinant Aurora-A in a kinase buffer
containing10 µCi of [γ-32P] ATP. After 30 min incubation, the reactions were separated
in SDS-PAGE and exposed to X-ray film. Histone H3 was used as a positive control and
GST-protein as a negative control (middle). The gel was subsequently stained with
Coomassie blue (bottom). (B) Aurora-A phosphorylates CHFR at 2 sites identified by
two-dimensional phosphopeptide mapping. The phosphorylated GST-CHFR-C2 protein,
which was extracted from SDS-PAGE mentioned in A, was digested by trypsin and
separated on TLC plate by electrophoresis at first-dimension and chromatography at
second-dimension. Each spot on the plate represents a phosphopeptide. (C) Aurora-A
phosphorylation of CHFR on serine residues. Phosphopeptides were recovered from TLC
plates. Following acid hydrolysis, phosphoamino acids were separated by twodimensional electrophoresis on TLC plates. Phosphoamino acid standards, which were
mixed with each sample, were visualized by staining with 0.25% w/v ninhydrin in
acetone. (D) The phosphopeptides were eluted from TLC plates and purified for manual
Edman degradation. During each cycle of Edman degradation, the most amino-terminal
amino acid was cleaved, and a sample from the reaction mixture is withdrawn. The free
phosphate, which can be separated from the peptide by electrophoresis, was released
where a phosphoserine or phosphothreonine residue is present.
To confirm this result, we converted Ser218 and Ser337 to alanine. In vitro kinase
assay, using wild-type GST-CHFR-C2, C2-S218A, C2-S337A and C2-S218/337A as
substrates, shows that mutation of either site or both significantly reduces Aurora-A
phosphorylation of CHFR (Fig. 3.4A). Further, immunoprecipitation and immunoblotting
analysis with anti-pS/T antibody revealed that Aurora-A phosphorylation of CHFR also
decreased in myc-CHFR single or double A-form mutants as compared to wild-type
CHFR (Fig. 3.4B). Therefore, Ser-218 and Ser-337 of CHFR are major residues targeted
by Aurora-A.
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Fig. 3.4. Confirm Aurora-A phosphorylation sites of CHFR. (A) In vitro kinase assay
using GST fused wild type CHFR, CHFR-S218A, -S337A and -S218/337A as substrates.
Recombinant Histone H3 was used as positive control (top). Bottom panel is Coomassie
blue staining showing equal amount of GST-CHFR protein used in the reaction. (B)
Western blot analysis. HEK293 cells were transfected with Myc-tagged wild type, S218A,
S337A and S218/337A CHFR expressing constructs together with HA-Aurora-A or
control vector. Following 48 h incubation, the cells were lysed and immunoprecipitated
using anti-Myc antibody. The immunoprecipitates were immunoblotted with antiphosphor-Ser/Thr antibody (top). Expression of the transfected CHFR and Aurora-A was
shown in panels 2 and 3. Relative phosphorylation levels of CHFR were normalized to
expression and quantified by ImageJ.
Mutation of the Phosphorylation Sites Abolishes CHFR E3 Activity
Since serine-218 is close to RF domain and seine-337 locates within the RF domain,
which is required for E3 activity (29), we reasoned that Aurora-A phosphorylation of
these 2 sites will decrease E3 activity of CHFR. In vivo ubiquitination assay was
performed using PLK1 as readout. HEK293 cells were transfected with HA-PLK1, HisUbiquitin, Myc-CHFR and HA-Aurora-A. Following treatment with a proteasome
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inhibitor MG132 for 6 hours, cells were lysed and subjected to Ni+-NTA-agarose beads
to pull-down His-tagged ubiquitin. The ubiquitin conjugated PLK protein was detected
by western blotting with anti-HA antibody. The result showed that a portion of PLK1 was
conjugated to ubiquitin in vivo. Ectopic expression of CHFR stimulated PLK1
polyubiquitination. Addition of Aurora-A reduced CHFR-induced PLK1 degradation (Fig.
3.5A), suggesting that Aurora-A negatively regulates CHFR ubiquitin ligase function.
We next examined if Aurora-A inhibition of CHFR E3 activity depends on
phosphorylation of serine-218 and serine-337. We created CHFR-S218/337D and CHFRS218/337A forms by converting serine residues to aspartic acids and alanines,
respectively. HEK293 cells were transfected CHFR, CHFR-S218/337D or CHFRS218/337A together with/without Aurora-A and then analyzed by Western blot for PLK1
expression. As expected, wild type CHFR reduced PLK1 protein level, which was
abrogated by expression of Aurora-A. Further, nonphosphorylatable CHFR-S218/337A
decreased PLK1 expression and Aurora-A failed to rescue it, whereas expression of
phospho-mimic CHFR was unable to reduce PLK1 protein (Fig. 3.5B). Thus, we
conclude that Aurora-A inhibits CHFR function through a phosphorylation-dependent
mechanism.
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Fig. 3.5. Aurora-A inhibits CHFR E3 activity through phosphorylation of Ser218
and Ser337. (A) In vivo ubiquitination assay. HEK293 cells were transfected with
indicated plasmids and treated with MG132. The cells were lysed and incubated with
Ni2+-NTA beads to pull-down His6-tagged protein. The ubiquitin conjugated PLK1 was
evaluated by Western blot analysis with anti-HA antibody. (B) Western blot. HEK293
cells were transfected with indicated expression constructs. Following 48 h incubation,
cells were lysed and immunoblotted with indicated antibodies. The relative PLK1 level
was normalized to actin and quantified by ImageJ.
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Discussion
In this study, we demonstrated that CHFR is a substrate of Aurora-A kinase. Aurora-A
phosphorylates CHFR at Ser218 and Ser337 and inhibits CHFR E3 activity. As a result,
its downstream targets, such as PLK1, become stable. Further, we also showed frequent
downregulation of CHFR and inverse correlation of expression of Aurora-A and CHFR
in human ovarian cancer, which supports the notion that CHFR is an E3 ligase of AuroraA (15). However, co-expression of CHFR and elevated Aurora-A was observed in a
subset of ovarian cancers, suggesting that Aurora-A might phosphorylate CHFR and
inhibit its tumor suppressor function in these tumors. Taken together, these findings
indicate a feedback regulation loop between Aurora-A and CHFR.
Previous studies have primarily focused on genetic alteration and normal cellular
function of CHFR. Posttranslational regulation of CHFR remains largely unknown. A
previous report shows that Akt/PKB phosphorylates CHFR at Thr-39 in FHA domain
after DNA damage, which led to inhibition of E3 activity and shortening G2 arrest
induced by DNA damage (30). In this study, we showed that Aurora-A inhibits E3
activity of CHFR by phosphorylation of Ser218 and Ser337, which are adjacent and
within RF region, respectively. Taken together, these data indicate that posttranslational
modification of CHFR plays a critical role in regulation of its function.
It has been suggested that R/K/N-R-X-S/T-B or R/KXT/S-I/L/V is Aurora kinase
phosphorylation consensus sequence, X represents any amino acid and B represents
hydrophobic residues with the exception of Pro (31). However, a number of Aurora-A
substrates identified so far do not contain this motif. While the serine-218 [PKGS(218)G]
of CHFR is not perfect match either sequence and the serine-337 [ERSS(337)L] does not
comply with R/K/N-R-X-S/T-B, they are phosphorylated by Aurora-A in vitro and in
vivo. Mutation of these 2 sites to aspartic acids, which mimic Aurora-A phosphorylation,
reduces E3 activity of CHFR and resemble the effect of Aurora-A phosphorylation of
CHFR, whereas CHFR-S218/377A retains its E3 activity that was not inhibited by
Aurora-A. Therefore, CHFR is a physiological substrate of Aurora-A and the Aurora-A
consensus phosphorylation motif could be more variable than originally expected.
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Aurora-A exerts its mitotic function through regulation of a number of proteins
(32-36), which include histone H3, TACC3, Eg5, CPEB and TPX2. We and others have
previously shown Aurora-A phosphorylation of p53 which leads to inactivation of p53
and G2/M cell cycle progression (20). CHFR has been shown to mediate a delay in cell
cycle progression early in mitosis in response to microtubule stress. Identification of
Aurora-A inhibition of CHFR provides additional molecular mechanism for Aurora-A
function in control of G2/M cell cycle progression.
Several groups have shown that CHFR mRNA expression is lost or decreased in
primary lung, colon, esophageal, gastric, brain, and breast tumors as well as cancer cell
lines. The best characterized means of expression loss is promoter hypermethylation,
which occurs in a subset of tumors and cell lines and the frequency of which seems to be
dependent on the tissue of origin (10-14). A recent report performed DNA sequence and
methylation specific PCR analyses and showed no mutation and hypermethylation in 48
ovarian cancers examined (37). However, we found frequent downregulation of CHFR
mRNA in both ovarian cancer cell lines and primary tumors by RT-PCR (Fig. 3.1). The
hypermethylation was only detected in 1 of 4 cell lines, which is consistent with the
previous findings that only a fraction of tumors with loss of CHFR expression are due to
promoter hypermethylation. Further investigation is required for determining the
mechanism of downregulation of CHFR in human cancer including ovarian carcinoma.
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CHAPTER IV
CYCLIN N-TERMINAL DOMAIN CONTAINING 2, CNTD2, IS AN ONCOGENE
THAT INTERACTS WITH AND ACTIVATES AURORA-A
Abstract
Cyclin N-terminal domain containing 2, CNTD2, is an uncharacterized cyclin. Here, we
identify CNTD2 as an Aurora-A interacting protein. CNTD2 colocalizes with Aurora-A
in the centrosome. Interaction between CNTD2 and Aurora-A leads to activation of
Aurora-A and cdc2 kinase, which promotes G2/M cell cycle progression. Further,
CNTD2 resides at chromosome 19q13.2 and is amplified and overexpressed in human
cancer cell lines and primary tumors of ovary, pancreas, breast, prostate and lung.
Alterations of CNTD2 appear to be associated with poor clinic outcome. Ectopic
expression of CNTD2 murine fibroblasts results in centrosome amplification, genomic
instability and malignant phenotype. These data suggest that CNTD2 is a key regulator of
Aurora-A and could play a pivotal role in cell cycle progression and oncogenesis.
Key words: amplicon, cyclin, cell cycle, cdc2, oncogenesis
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Introduction
Aurora-A is a mitotic kinase, which localizes to centrosome and regulates cell cycle
progression through modulating centrosome function. Aurora-A is amplified and/or
overexpressed in a range of human cancers, including breast, ovarian, colon, bladder and
pancreatic cancers (1-5). Aurora-A overexpression in cultured cells leads to centrosome
amplification, multipolar spindle and polyploidy, resulting in cell-cycle checkpoint
defects and genetic instability, which contributes to malignant transformation. Aurora-A
executes regulatory and transforming function through its kinase activity, which is
regulated by phosphorylation and dephosphorylation as well as association with a number
of proteins such as HEF1, TPX2, or Bora (6-8).
Genetic and chromosomal abnormalities, including amplification, deletion and
aneuploidy in chromosomes, are common features associated with cancer development
and progression (9,10). Amplified chromosomal regions, known as amplicons, have been
implicated in a wide variety of cancers. Well-known amplicons in cancer include
chromosome 17q12 containing ErbB-2 (11,12), chromosome 7q11.2 containing EGFR
(13), 20q13 containing Aurora-A (14), chromosome 19q13.1-q13.2 containing AKT2
(15), chromosome 11q13 containing CCND1 and EMS1 (16,17), chromosome 12q13–14
containing MDM2 (18,19), N-Myc amplification on chromosome 2p24 (20-22), newly
discovered co-amplification of PI3KCA and ZASC1 on 3q26.3 (23) and chromosome
19q12 containing CCNE1 (24). Studies on these genes not only have provided new
insights on how cancer develops but also have significant translational implications. For
example, ErbB-2 and EGFR are the molecular targets for the humanized antibodies
Trastuzumab (Herceptin) and Matuzumab, which are used for the treatment of breast and
lung cancer, respectively (25,26).
The two major processes common to all cell cycles are S phase, when
chromosomes are replicated, and M phase, when the replicated chromosomes are
segregated into two daughter cells. In most cell cycles, an interval of time, G1 phase,
separates the previous cell division from the beginning of the next S phase. It is now
firmly established that progression of the cell cycle — that is, transitions between one
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phase of the cycle and the next — are controlled by cyclin-dependent kinases (CDKs).
The CDK regulating G2/M transition is CDK1/Cdc2, which is the major mitotic kinase.
Cdc2 interacts with B-type cyclins to form a stoichiometric complex, known as mitosispromoting factor (MPF). Binding of the cyclin subunit is required for the phosphorylation
and activation of the Cdc2 subunit by cdk-activating kinase (CAK). Two B-type cyclins,
B1 and B2, have been identified in mammals. Cyclin B1 was first cloned at 1989, and
found predominantly expressed in the G2/M phase of cell division.
In this study, we identified hypothetical protein FLJ13625 as an Aurora-A
interacting protein by yeast two-hybrid screening. The coding region of this protein maps
to chromosome 19q13 amplicon. Sequence analysis showed that this protein contains a
cyclin domain (CD) at C-terminus, and it is homologous to yeast B-type cyclin 6 (clb6).
The protein is identical to human cyclin N-terminus Domain containing protein 2
(CNTD2), only with a cyclin domain that is 30 amino acids longer than CNTD2.
Therefore, we consider it as an alternative splice form of CNTD2. Like Aurora-A,
CNTD2 localizes to the centrosome and activates Aurora-A and cdc2. Further, the
CNTD2 gene is amplified and overexpressed in human cancer. Ectopic expression of
CNTD2 is able to cause centrosome amplification, genomic instability and oncogenic
transformation in 3Y1 cells.
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Materials and Methods
Cell Culture, Transfection and Treatment
Human cancer cell lines (MDA-MB-231, MDA-MB-435s, MDA-MB-453, MDA-MB468, T47D, UTOV2, UTOV3A, UTOV5, UTOV7, DU145, D32, U118, PANC-1,
Colo357, SW480 and HeLa) and HEK293 cells were maintained in Dulbecco modified
Eagle medium (DMEM). Cells cultured in RPMI 1640 medium are OV3, OV8, OV2008
C13, MCF7, LNCaP, PC3, AsPC-1 and A549 cells. Ovarian cancer SW626 cells were
cultured in 50:50 medium M199:MCDB105; A2780S, A2780CP and RMUG-S were
grown in DMEM/F-12 medium. MCF10A cells were maintained in Mammary Epithelial
Growth Medium (MEGM). HCT116 was cultured in McCoy’s 5A medium. All culture
mediums were supplemented with 10% fetal bovine serum (FBS). Rat fibroblast cell line
3Y1 was cultured in DMEM containing 10% calf serum. Transfection was performed
with LipofectAMINE 2000 reagent (Invitrogen). For protein degradation assay, cells
were treated with cycloheximide (CHX) at a concentration of 50 µg/ml for 6 hours.
Plasmid Constructions
For yeast two-hybrid screening, the N-terminal portion of Aurora-A encoding amino
acids 1 to 110 was cloned into the EcoR1 and BamH1 sites of pJK202 to create the bait
pNLexA-Aurora-AN. The oligonucleotide primers used were as follows: forward, 5′ATGGACCGATCTAAAGAAAACTGC-3′, and reverse 5’AGGATTATTTTCAGGTGCCGATG.
The coding sequence of CNTD2 was ligated to pGEX4T-1 vector to generate
GST-CNTD2 fusion protein (Pharmacia). HA-CNTD2 was constructed by cloning
CNTD2 into EcoR1/Not1 of pHM6 vector; Flag-CNTD2 was cloned by insertion of
EcoR1/BamH1 digested CNTD2 into p3×FLAG/CMV10 and/or pIRESflagEGFP2
vectors, respectively. Inducible CNTD2 was obtained by cutting out flag-CNTD2
sequence from pIRES2-flag-CNTD2 and ligated into pTRE2hyg2-HA vector through
PvuII site. The primers were: H_CNTD2-1 (forward), 5’77

CGCGGATCCGCGAATTCCATGCTGGTGAGAGGCAGGGACCAG-3’, and
H_CNTD2-2 (reverse), 5’-CGCGGATCCGCGGCCGCTTACTCCCTGCCCTGAAAG3’.
Yeast Two-Hybrid Screen
A genetic screen using the yeast two-hybrid system was performed as previously
described (27). Briefly, yeast strain EGY191, which harbors the LexAop-Leu2 reporter
gene, was transformed with bait plasmid pNLexA-Aurora-AN and reporter plasmid
pSH18-34 and subsequently transformed with a human brain interaction library.
Approximately 2 × 106 primary library transformants were obtained and plated on Ura−
His− Trp− Leu− galactose-raffinose plates. Candidate clones were identified by their
ability to grow on Ura− His− Trp− Leu− galactose-raffinose plates, but not on Ura− His−
Trp− Leu− glucose plates, and their ability to yield blue colonies on Ura− His− Trp− X-Gal
(5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside)-galactose-raffinose plates, but not
on Ura− His− Trp− glucose plates. KC8 cells were transformed with plasmids isolated
from positive colonies. The specificity of interaction of candidate plasmids with
pNLexA-Aurora-AN was tested by retransformation of positive clones into yeast
harboring either the aurora-A bait or several unrelated bait plasmids. Nucleotide sequence
analysis of cDNA inserts was performed using an Applied Biosystems automated
sequencer.
Western Blotting and Immunoprecipitation
Cells were lysed for Western blotting analysis in RIPA buffer (50 mM NaCl, 0.5% (w/v)
DOC, 50 mM Tris-HCl (pH 8.0), 1% (v/v) NP-40, 0.1% (w/v) SDS, 1µg/ml aprotinin,
1µg/ml leupeptin, 0.5mM Na3VO4 and 1mM PMSF). The proteins were resolved under
denaturing condition by SDS-polyacrylamide gel and transferred onto Nitrocellulose
(Amersham) membranes. The membranes were blocked and then incubated with
appropriate antibodies indicated in figure legends.
For immunoprecipitation (IP), cells were lysed in TNEN buffer containing 50 mM
Tris-HCl (pH 7.5), 50-150 mM NaCl, 2 mM EDTA, 0.5% (v/v) NP40, 0-0.3% (v/v)
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Triton X-100, protease and phosphatase inhibitors (1µg/ml aprotinin, 1µg/ml leupeptin,
0.5mM Na3VO4 and 1mM PMSF). Precleared-lysates were incubated with 30µl antibody
conjugate protein A:G (2:1) agarose beads at 4°C overnight. Following 3 times washing,
the precipitates were denatured and subjected to Immunoblotting with the antibodies
indicated in figure legends.
Northern and Southern Blot
Total RNA was isolated from cells using Trizol Reagent (Invitrogen). Northern blot
analysis was performed as previously described (15). Briefly, 20 µg total RNA from each
sample was separated on 1.0% denature agarose gel. After transferring to GeneScreen
Plus Membrane (PerkinElmer) and prehybridization, the membrane was hybridized with
[32P]dCTP-labeled Aurora-A cDNA probe in Express-Hybridization Solution (Clontech).
For Southern blot, 10 µg of genomic DNA extracted from cancer cell lines was
digested by EcoR I in 100 µl volume overnight, then precipitated with 2.5 folds of icecold 100% ethanol. The digested and purified DNA was subjected to 0.8% agarose gel
electrophoresis at 40 volts for 16 hours. After transfer, the membrane was hybridized
with radioactive labeled CNTD2 probe. The probe was obtained from PHM6-CNTD2 by
restriction enzyme digestion with EcoR I and Not I. The cDNA fragment was gel purified
and resuspended in TE buffer, then labeled with [32P]-dCTP using Prime It® II Random
Primer Labeling Kit (Stratagene).
Indirect Immunofluorescence (IIF)
Cells were seeded on 2 cm × 2 cm coverslips in 6-well plates, the coverslips were pretreated with poly-L-Lysine as needed. After expression of transfected proteins or
appropriate treatment, cells were fixed and penetrated by 4% paraformaldehyde + 0.2%
Triton X-100 in PBS/Mg (0.5 mM MgCl2) 10 min at room temperature. Following 4
times wash in PBS/Mg, cells were stored at 4°C or proceeding to blocking. Non-related
antigens were blocked by incubating in Knudsen Modified Blocking buffer (0.5% BSA,
0.5% NP-40, 1 mM MgCl2, 1 mM NaN3 in 1×PBS) 1 hour at room temperature. After
removing the blocking buffer, cells were incubated with diluted primary antibodies for 2
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hour at room temperature or 4°C overnight. Multiple primary antibodies of different
origins were combined. Fluorescence conjugated secondary antibodies were applied at
appropriate dilutions after washing off the primary antibodies. Following final washes by
PBS/Mg, coverslips were mounted onto glass slides using VECTASHIELD mounting
medium (with DAPI) (VECTOR), which stains DNA while mounting. All the steps were
performed in humidified chamber and in dark if fluorescence was present. The slides
were kept in dark at 4°C before viewed by ZEISS automated fluorescent scope.
In vitro Aurora-A, p34cdc2 Kinase Assay
Aurora-A kinase assay was performed as previously described (28). Briefly, reactions
were carried out in the presence of 10 µCi of [γ-32P] ATP (Perkin Elmer Life Sciences)
and 1 nM cold ATP (Invitrogen) in 30 µl kinase buffer containing 16.5 mM MOPS (pH
7.0), 0.375 mM EDTA, 2.25 mM EGTA, 33.75 mM MgCl2, 225 µM ATP (cold), 11.25
mM β-glycerophosphate, 0.45 mM Na3OV4, 0.5 mM DTT, 0.0125% (v/v) 2mercaptoethanol, and 0.625% (v/v) glycerol. 4 µg recombinant Histone H3 used as
substrate. After incubation at 30°C for 30 min, the reaction was stopped by adding
protein loading buffer and denaturing. The proteins were separated by SDS-PAGE, and
the amounts of incorporated radioactivity were determined by autoradiography.
p34cdc2 kinase activity was measured as previously described (29). Briefly,
transfected Hela cells were lysed in buffer containing 50 mM Tris-HCl (pH 8.0), 0.5%
Nonidet P-40, 2 mM EDTA, 137 mM NaCl, 10% glycerol, 2 mM sodium vanadate, 100
mM leupeptin, and 1 mM phenylmethylsulfonyl fluoride. 500 µg of protein were
incubated with anti-cyclin B antibody conjugated protein A/G-agarose beads in 1 ml lysis
buffer at 4 °C for at least 4 hours. Followed 3 times washing, beads-bond cdc2/cyclin B
complexes were incubated at 30 °C with [γ-32P]-ATP and Histone H1 in a buffer
containing 100 mM NaCl, 10% Triton X-100, 50 mM ATP and 10 mM MgCl2. The
reaction product was resolved by SDS-PAGE and exposed to autoradiography.
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Soft Agar Assay and Tumorigenicity in Nude Mice
Soft agar assay was performed as previous described (30). 2×105 of CNTD2-transfected
3Y1 cells were suspended in 5 ml of 0.33% (w/v) agar containing DMEM/20% fetal calf
serum, overlaid onto a 10 ml volume 0.66% agar solution in 10 cm plates. The cultures
were fed twice a week for 4 weeks.
Tumor formation in 6-week old NOD SCID mice (Jackson Laboratory) was tested
by subcutaneous inoculation and assessed for 6 weeks. 3Y1 cells transfected with
CNTD2 or control vector were each injected into 8 animals at 5×106 cells per mouse.
Tumor measurements were made with linear calipers in two orthogonal directions by the
same observer.
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Results
Identification of CNTD2 as an Aurora-A Interacting Protein
In order to understand Aurora-A function and its involvement in molecular pathways, we
performed yeast two-hybrid screening using N-terminal region of Aurora-A as bait. Two
overlapping clones were isolated from a human brain library. Sequence analysis revealed
that it encodes a longer splicing form of human cyclin N-terminal domain containing 2
(CNTD2), with extra 30 amino acids that insert between residues 89 and 90 of CNTD2.
CNTD2 is an uncharacterized B-type cyclin which contain a C-terminal cyclin domain
and an N-terminal CDK5 activator homology region (Fig. 4.1A). The amino acid
sequence differs substantially from those of the well characterized cyclins but is similar
to hypothetical protein LOC779739 in Xenopus tropicalis (similarity 70%; identity 50%)
and clb6 in Saccharomyces cerevisiae [similarity, 60%; identity, 42%; (Fig. 4.1B)].
To confirm the interaction between Aurora-A and CNTD2, we performed
coimmunoprecipitation experiment in HEK293 cells that were transfected with HAtagged-CNTD2 and/or GFP-Aurora-A. Antibody against GFP was able to
immunoprecipitate CNTD2, which is detected by HA antibody, from cells co-transfected
with both Aurora-A and CNTD2, but not cells transfected with either Aurora-A or
CNTD2 alone. In addition, HA-CNTD2 also co-precipitated with GFP-Aurora-A (Fig.
4.2A). Furthermore, antibodies against endogenous Aurora-A or CNTD2 identified the
physical interaction of between Aurora-A and CNTD2 (Fig. 4.2B).
CNTD2 Colocalizes with Aurora-A in Centrosome
Since Aurora-A is a centrosome kinase and interacts with CNTD2, we next examined if
CNTD2 confine to centrosome and colocalizes with Aurora-A. HeLa cells were
transfected with GFP-tagged-CNTD2 and then immunostained with antibody against γtubulin, a centrosome marker. As shown in Fig. 4.2C, CNTD2 localizes to centrosome
during the cell cycle. Co-immunofluorescence staining of HeLa cells with anit-CNTD2
and -Aurora-A antibodies revealed that CNTD2 and Aurora-A co-localize in the
centrosome. These observations further indicate CNTD2 interaction with Aurora-A.
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Fig. 4.1. CNTD2 sequences. (A) Domain structure of human CNTD2 (longer splicing
form). CDK5_a, CDK5 activator homology region; CYCLIN, cyclin domain. (B)
Sequence alignment of human CNTD2 and yeast clb6 by ClustalW2 program. Cyclin
domains of CNTD2 and clb6 were highlighted in purple and grey color, respectively.
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Fig. 4.2. Interaction and colocalization of CNTD2 and Aurora-A. (A and B) Coimmunoprecipitation. HEK293 cells were co-transfected with GFP-Aurora-A and HACNTD2, and immunoprecipitated with anti-HA and detected with anti-GFP antibody (top
panel) or vise versa (second panel). Panels 3 and 4 show expression of transfected
plasmids (A). PANC1 cells were lysed and immunoprecipitated with anti-AurA or antiCNTD2 antibody and immunoblotted with anti-CNTD2 or anti-AurA antibody,
respectively (B). (C) Immunofluorescence staining. As shown in upper panel, GFPCNTD2 (green) transfected Hela cells were synchronized to mitosis and centrosomes was
stained with anti-γ-tubulin antibody followed by TRITC-conjugated secondary antibody
(red); in lower panel, mitotic arrested HeLa cells were stained with anti-CNTD2 and anti84

Aurora-A antibodies. CNTD2 was shown in red (TRITC), Aurora-A was shown in green
(FITC), and the nucleus was stained by DAPI.
CNTD2 Stabilizes Aurora-A Protein and Stimulates Aurora-A Kinase Activity
We next investigated the regulation between CNTD2 and Aurora-A. As Aurora-A is a
serine/threonine protein kinase, we first examined if CNTD2 is a substrate of Aurora-A.
In vivo phosphorylation and in vitro kinase assays exhibited no phosphorylation of
CNTD2 by Aurora-A (data not shown). However, ectopic expression of CNTD2
increases Aurora-A protein but not mRNA levels in a dose-dependent manner. In Tet-On
inducible CNTD2 HeLa cells, Aurora-A protein level was upregulated upon CNTD2
expression induced by doxycycline (Fig. 4.3A). To determine if CNTD2 inhibits AuroraA degradation, HeLa cells were treated with CHX to block de-novo protein synthesis. As
shown in Fig. 4.3B, without induction of CNTD2, Aurora-A protein degradated rapidly
with 20% decrease in an hour. Once CNTD2 was expressed, Aurora-A protein became
more stable and reached the same degradation level (20%) until 6 hours after CHX
treatment.
Aurora-A kinase is activated during G2/M phase due to the fact that Aurora-A is
accumulated and interacts with TPX2 through its C-terminal hydrophobic region (7). In
addition, we have previously shown that Aurora-A kinase activity is closely associated
with Aurora-A protein levels in human cancers (4). Thus, CNTD2 could activate AuroraA through upregulation or/and interaction with Aurora-A. To this end, Aurora-A kinase
activity was examined in both CNTD2-inducible and -knockdown cells. Following
treatment of Tet-On CNTD2 HeLa cells with doxycycline for 12 h and 24 h, Aurora-A
was immunoprecipitated with anti-Aurora-A antibody. In vitro kinase assay showed an
increase in Aurora-A kinase activity in both time points (Fig. 4.3C), when the Aurora-A
protein expression was induced (Fig. 4.3A). Further, knockdown of CNTD2 in PNAC1
cells, in which CNTD2 is amplified (Fig. 4.5B), reduced Aurora-A kinase activity,
especially in mitotic cells in which Aurora-A protein and activity reach the peak (Fig.
4.3D).
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Fig. 4.3. CNTD2 stabilizes Aurora-A protein and induces Aurora-A kinase activity.
(A) Aurora-A is upregulated by CNTD2. HeLa-TetOn-CNTD2 cells were treated with
doxycycline for indicated times and immunoblotted with indicated antibodies. (B)
CNTD2 inhibits Aurora-A degradation. HeLa-Tet-on-CNTD2 cells were treated with or
without doxycycline overnight. Following addition of CHX for indicated times, cells
were subjected to Western blot analysis with indicated antibodies. (C) CNTD2 induces
Aurora-A kinase activity. Following treatment with and without doxycycline, HeLaTetOn-CNTD2 cells were lysed and the endogenous Aurora-A was immunoprecipitated
by anti-Aurora-A antibody and subjected to in vitro kinase assay using Histone H3 as
substrate. (D) Knockdown of CNTD2 decreases Aurora-A kinase activity. PANC1 cells
were transfected with scramble or CNTD2 siRNA, and selected by puromycin.
Endogenous CNTD2 protein was analyzed by Western blot (right). Following treatment
with or without nocodazole, cells were immunoprecipitated with anti-Aurora-A antibody
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and subjected to in vitro Aurora-A kinase assay. The Aurora-A protein and activity were
normalized to expression and quantified by ImageJ software.
CNTD2 Promotes G2/M Progression and Activates cdc2 Activity
Since Aurora-A activates cdc2 activity and promotes G2/M progression by regulation of
mRNA polyadenylation of cyclin B1 through phosphorylation of cytoplasmic
polyadenylation element binding protein (CPEB) (31), we next examined the effects of
CNTD2 on cell cycle progression and cdc2 activity. CNTD2 inducible HeLa cells were
synchronized by double-thymidine block and simultaneously treated with doxycycline or
DMSO at the second thymidine block. Cell cycle analysis showed that CNTD2-cells
reached G2/M peak at 6 hours after release from the double-thymidine block as compared
to control cells, in which G2/M accumulation appeared at 9 hours of release (Fig. 4.4A).
Further, knockdown of CNTD2 delayed G2/M cell cycle progression (Fig. 4.4B).
To investigate the effect of CNTD2 on cdc2 kinase activity, in vitro cdc2 kinase
assay was performed in CNTD2-inducible and control-TetOn Hela cells. After treatment
with doxycycline for 12 h and 24 h, cells were immunoprecipitated with anti-cyclin B1
antibody and cdc2 activity was measured by in vitro kinase assay using Histone H1 as
substrate. Induced expression of CNTD2 in Hela-TetOn-CNTD2 cells significantly
induced cdc2 kinase activity; whereas in control cells where there is no CNTD2
expression, cdc2 activity was not affected by doxycycline treatment (Fig. 4.4C).
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Fig. 4.4. CNTD2 promotes G2/M progression and stimulates cdc2 kinase activity. (A
and B) CNTD2 promotes G2/M progression. Following induction of CNTD2 by
doxycycline, HeLa-TetOn-CNTD2 cells were synchronized to G1/S with doublethymidine block. After release for indicated times, cells were assayed with flow
cytometry (A). PANC1 cells were stably transfected with siRNA of CNTD2 and control
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siRNA. After treatment with hydroxyurea for 16, cells were released for indicated times
and subjected to flow cytometry analysis (B). (C) CNTD2 induces cdc2 activity. HeLaTetOn-CNTD2 and control cells were treated with doxycycline and immunoprecipitated
with anti-cyclin B antibody. The cdc2 kinase activity was assayed using Histone H1 as
substrate and quantified by ImageJ.
CNTD2 is Ubiquitously Expressed in Normal Tissues and is Frequently Altered in
Human Cancers
Northern and Western blot analyses revealed ubiquitous expression of CNTD2 in
different normal mouse tissues (Fig. 4.5A) and human cancer cell lines. Notably, two and
three different transcripts were observed in the cell lines examined with elevated levels of
CNTD2 in HL60 and Raji cells (Fig. 4.5B). However, expression levels of CNTD2,
unlike Aurora-A, is not changed during the cell cycle (Fig. 4.5C).
Genomic database analysis shows that CNTD localizes to chromosome 19q13.2
within the 19q13.1-13.2 amplicon (Fig. 4.6A). Amplification of chromosome 19q13 has
been linked to different types of cancers including pancreatic carcinoma (32-34), ovarian
carcinoma (35-37), breast cancer (38) and other cancers (39-41). Interestingly, CNTD2 is
32-kb centromeric to AKT2, an oncogene frequently amplified in human cancer. To
investigate if CNTD2 is also altered in human cancer, we performed Southern blot
analysis in 18 cancer cell lines and found that CNTD2 was amplified in PANC1, ASPC1
and OV3 cells (Fig. 4.6B), in which AKT2 is also amplified (15,32).
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Fig. 4.5. CNTD2 expression in normal tissues and human cancer cell lines. (A)
CNTD2 protein expression in normal mouse tissues shown by Western blot. (B) Northern
blot membrane from Clontech was hybridized with CNTD2 probes. Human cancer cell
lines examined: 1. HL60, 2. Hela S3, 3. K562, 4. MOLT-4, 5. Raji, 6. SW480, 7. A549, 8.
G361. (C) Hela cells were synchronized and collected at different time points for
Northern, Western blot and cell cycle analyses.
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Fig. 4.6. CNTD2 is amplified in human cancer cell lines. (A) CNTD2 locates to
chromosome 19q13.2 close to AKT2. (B) Southern blot analysis. DNAs from indicated
cell lines were digested with EcoRI and electrophoresed in 0.8% agarose gel. After
transferring, a membrane was hybridized with [32P]-dCTP labeled CNTD2 (top) and βactin (bottom) probes.
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We further examined the expression of CNTD2 protein in human cancer cell lines.
Immunoblotting analysis revealed an elevated CNTD2 protein level in 3 of 8 breast
cancer, 5 of 10 ovarian cancer and 2 of 4 prostate cancer cell lines examined (Fig. 4.7A).
The majority of cell lines with overexpression of CNTD2 protein did not have change at
DNA level, suggesting that amplification of CNTD2 is responsible for increase in its
protein expression in a small subset of cell lines.
To determine the expression level of CNTD2 in human primary tumors, we
analyzed 18 pairs of lung cancer and normal samples for CNTD2 protein expression.
Fifteen (83%) tumor samples showed increased CNTD2 level compared to the adjacent
normal tissues (Fig. 4.7B). We further investigated the alteration of CNTD2 in ovarian
cancer due to the fact that chromosome 19q13 is frequently amplified in this malignancy.
Western blotting and immunohistochemistry analyses revealed overexpression of CNTD2
in 35 of 65 (54%) ovarian tumors, whereas only 3 of 10 normal ovary samples expressed
moderate to low levels of CNTD2 (Figs. 4.8A and 4.8B; Table 3). No significant
correlation was found between CNTD2 protein levels and histological types (Table 4).
However, more frequent overexpression of CNTD2 was observed in late stage and, more
significantly, high grade tumors (Table 5). We also analyzed the association of the
expression of CNTD2 with the ovarian cancer patients’ survival. Kaplan-Meier curves
analysis of 65 patients with ovarian tumors demonstrated a statistically significant
negative correlation between patient overall survival time and CNTD2 expression level
(P = 0.05; Fig. 4.8C). These results suggest that CNTD2 is a candidate oncogene in
chromosome 19q13 amplicon and could play a role in human oncogenesis and that its
alterations are recurrent events in human cancer and associated with tumor progression
and poor clinical outcome in ovarian carcinoma.
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Fig. 4.7. CNTD2 is overexpressed in human cancer. (A) Elevated levels of CNTD2 in
human cancer cell lines. Cell lysates from indicated cell lines were immunoblotted with
anti-CNTD2 (top) and -actin (bottom) antibodies. (B) Overexpression of CNTD2 in
primary lung cancer. Tissue lysates from paired normal lung and tumor specimens were
assayed by Western blot analysis with indicated antibodies.
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Fig. 4.8. Overexpression of CNTD2 in ovarian tumors is associated with poor
prognosis. (A) Western blot. Human primary ovarian tumors were immunoblotted with
anti-CNTD2 and -actin antibodies. (B) Immunohistochemical staining. Representative
tumors were immunostained with anti-CNTD2 antibody. (C) Overall survival in patients
with high CNTD2 (n = 35) versus the remaining patients (n = 30) was plotted by the
Kaplan-Meier method. Statistical comparison of survival between groups with the logrank statistic suggests that patients with overexpression of CNTD2 in the tumor had poor
survival compared with low and no expression (P = 0.018).
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Table 3. CNTD2 expression in ovarian tumors and normal tissues.

Table 4. Association of CNTD2 expression with tumor histological types.

Table 5. Correlation of CNTD2 expression level with tumor grade and stage.

Ectopic Expression of CNTD2 Induces Malignant Transformation
To determine CNTD2 oncogenic activity, we stably transfected 3Y1 cells with pHM6HA-CNTD2 and vector alone. pHM6 vector-transfected 3Y1 grew in monolayer with
fibroblast feature, whereas CNTD2 stably-transfected cells exhibited epithelial
morphology, larger nucleus and lost their contact inhibition (Fig. 4.9A). Further, CNTD2
cells grew much faster than control cells, suggesting the role of CNTD2 in regulating cell
proliferation (Fig. 4.9B).
95

Furthermore, soft agar assay was carried out to investigate anchorage-independent
growth. Colonies of CNTD2-transfected cells appeared microscopically after 10 days and
became visible to the naked eye after 20 days of incubation. Colonies were not observed
in soft agar cultures of parental 3Y1 cells or of cells transfected with pHM6 vector (Fig.
4.9C). To investigate the tumorigenic activity of CNTD2, clonal cell lines were injected
subcutaneously into nude mice. All mice inoculated with CNTD2 transfected cells
formed tumors within 14-21 days following injection, whereas vector-transfected 3Y1
cells did not develop tumors until over 2 months (Fig. 4.9D and Table 6). Western blot
analysis revealed expression of CNTD2 protein only in pHM6-HA-CNTD2-transfected
cells and tumors.

Fig. 4.9. Ectopic expression of CNTD2 transforms 3Y1 cells. (A) Cell morphology.
CNTD2- and vector-transfected 3Y1 cells were observed under microscope. (B) Cell
growth curve. CNTD2-transfected and control 3Y1 cells were plated in 96-well plates
and cell number was calculated daily for 6 days. (C) CNTD2-transfected but not control
3Y1 cells grew in soft agar. (D) Tumor formation in nude mice. CNTD2-transfected and
control 3Y1 cells were subcutaneously injected into nude mice (5 × 106 cells/mouse; 8
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mice/group). Tumor formation was observed in all the mice injected with CNTD2transfected cells and in 1 of 8 mice received mock cells. Western blot showed CNTD2
expression in dissected tumors.
Table 6. Tumorigenicity of CNTD2 and control transfected 3Y1 cells.

CNTD2 Expression Induces Centrosome Amplification and Genomic Instability
Since CNTD2 localizes to centrosome and induces transformation, we hypothesized that
overexpression of CNTD2 causes centrosome amplification and aberrations in
chromosome partitioning at mitosis, leading to catastrophic loss or gain of chromosomes
and resulting in either cell death or survival through malignant transformation. To test
this hypothesis, we immunofluorescence-stained CNTD2-transformed 3Y1 and control
cells with anti-γ-tubulin and -HA (e.g., CNTD2) antibodies (Fig. 4.10A). Fig. 4.10 shows
that control 3Y1 cells have either 1 (interphase) or 2 centrosomes (dividing). However,
the number of centrosomes is significantly increased in CNTD2-transformed cells.
Approximately 28% of CNTD2 transfectants revealed more than two centrosomes,
compared with less than 3% of the vector-transfected cells showing a similar phenotype
(Fig. 4.10B).
Centrosome amplification is related to abnormal cell division, chromosome
instability and cancer development (42). Chromosomal analysis showed that most (42 of
50) vector-transfected 3Y1 cells were near-diploid, whereas 39 of 50 (78%) metaphases
from CNTD2-transfected cells were polyploid. Among these 39 metaphase spreads, 23
were near-tetraploid and contained one or two small marker chromosomes, and the
remaining 16 metaphases had chromosome counts ranging from 132 to more than 600
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(Fig. 4.10C). One metaphase contained a ring chromosome and numerous (>50) small
markers, fragments and double minutes. Thus, overexpression of CNTD2 induces
genomic instability.

Fig. 4.10. CNTD2 induces centrosome amplification and genomic instability. (A)
HeLa cells were immunostained with anti-γ-tubulin (left) and anti-CNTD2 (middle)
antibodies. CNTD2 colocalizes with γ-tubulin (right panel). (B) CNTD2-transfected and
control 3Y1 cells were immunostained with anti-γ-tubulin antibody (left). The number of
centrosome was counted in both CNTD2-transfected and control cells, 200 events each
(right). (C) Karyotype analysis of CNTD2-transfected and control 3Y1 cells.
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Discussion
Using the amino-terminal region of Aurora-A as bait in a yeast two-hybrid screen, we
have identified a novel B-type cyclin, CNTD2. CNTD2 colocalizes and
immunoprecipitates with Aurora-A. The interaction results in stabilization Aurora-A
protein and activation of Aurora-A kinase. CNTD2 is conserved between yeast, Xenopus
and human cells. CNTD2 locates to chromosome 19q13 amplicon. Amplification and/or
overexpression of CNTD2 were detected in human cancer cell lines and primary tumors.
Ectopic expression of CNTD2 induces transformation, centrosome amplification and
genomic instability. These findings indicate that CNTD2 functions as an oncogene and is
associated with and regulates Aurora-A.
In mammalian cells, the Aurora kinase family has three members: Aurora-A, -B,
and -C. Aurora-A expression up-regulates at mitosis and it localizes at centrosome and
mitotic spindles. Aurora-A T288 phosphorylation activates its kinase activity in late G2
phase at centrosomes, which is prior to and required for the recruitment of cdc2-cyclin
B1 to the centrosome. The activated cdc2-cyclin B1 then commits the cell to mitosis (43).
While CNTD2 interacts with Aurora-A and activates Aurora-A and cdc2 kinase activity,
it does not form complex with cdc2 (data not shown) and its protein level is relative
stable through the cell cycle. Since N-terminal region (aa 1-110) of Aurora-A, which is
required for interaction with CNTD2, is different from those of Aurora-B and Aurora-C,
we found no interaction between CNTD2 and Aurora-B or Aurora-C (data not shown).
The kinase activity of Aurora-A is regulated by autocatalytic phosphorylation of
Thr288 in its activatory T-loop (44). This autocatalytic activity of Aurora-A is facilitated
by cofactors such as Bora, Ajuba, PAK1, HEF1 and TPX2 (6,8,43,45,46). The
mechanism of cofactor-mediated Aurora-A activation is best understood in the case of
TPX2. Co-crystallisation revealed that binding of TPX2 to Aurora-A not only induces it
to adopt an active conformation but also prevents dephosphorylation of Thr288 by protein
phosphatase 1 (PP1) (47). TPX2, Bora and Ajuba are also substrates of the kinase (7,8,43).
Unlike these Aurora-A interaction proteins, CNTD2 increases Aurora-A protein stability
and kinase activity but is not phosphorylated by Aurora-A.
99

Several oncogenes have been identified from chromosome 19q13 amplicon,
including AKT2, PAK4, pancreatic differentiation 2 (PD2), SERTAD3 and
transcriptional regulator intersex-like (IXL) (15,48-51). We have previously shown
amplification/overexpression of AKT2 in human ovarian, pancreatic and breast cancers.
Inhibition of AKT2 inhibits tumor growth and sensitizes cells to chemotherapeutic agentinduced cell death (15,52,53). In this report, we demonstrated that CNTD2 resides
between AKT2 and PAK4 and is amplified/overexpressed in human ovarian, pancreatic
and lung cancers. Overexpression of CNTD2 is associated with late stage/high grade
ovarian tumors and accompanied with poor clinic outcome. Therefore, CNTD2 could be
a potential therapeutic target for these malignancies. Future investigations are required
for characterization of the molecular mechanism of CNTD2 stabilization and activation
of Aurora-A as well as the role of CNTD2 in oncogenesis in vivo.
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CHAPTER V
DISCUSSION AND CONCLUSION
Aurora kinases represent a novel family of serine/threonine kinases crucial for cell cycle
control. The first Aurora kinase was discovered in Drosophila (1). Because its mutations
resulted in a failure of centrosome separation, leading to the formation of monopolar
spindles, it was given the name "Aurora," reminiscent of the North Pole. The mammalian
Aurora family comprises three related kinases that share the highest degree of sequence
homology in their catalytic domains (2, 3). The Aurora-A and -B kinases have emerged
as essential regulators of cell division. While Aurora-A is implicated in regulating mitotic
entry, centrosome maturation, and spindle assembly; Aurora-B is required for correct
chromosome segregation and cytokinesis. For Aurora-C, expression seems to be
restricted to normal testicular tissue, the normal function of which is not well documented
until recent reports show that Aurora-C is also a chromosomal passenger protein, and that
it binds directly to INCENP and survivin in vitro (4-6). Experimental data suggest that
inappropriately high or low levels of Aurora kinase activity are linked to genetic
instability. Despite their sequence homology and common association with cycling cells,
the subcellular distribution, partners, and substrates and therefore functions of Aurora-A
and -B are essentially nonoverlapping (7, 8).
In this work, we focused on Aurora-A kinase. Through study of upstream
regulator, downstream target and functional associating partner (Fig. 5.1), we provided
new insights into better understanding of the molecular mechanism of Aurora-A kinase in
human oncogenesis.
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Aurora-A alteration is found in various human malignancies, at mRNA and/or
protein levels more than DNA copy number change (9-11). The discrepancy suggests that
Aurora-A overexpression is likely to be regulated not only by gene amplification, but also
by other mechanisms such as transcriptional or translational activation and suppression of
protein degradation. However, transcriptional regulation of Aurora-A during the cell
cycle is largely unknown. We demonstrated, for the first time, that transcription factor
E2F3 directly binds to Aurora-A promoter and tightly regulates Aurora-A expression
during G2/M phase, which provides a mechanism for regulation of Aurora-A at
transcription level during the cell cycle.
Among the 8 E2F family members identified so far, the transcriptional activators
E2F1–3 have been shown to be cell cycle regulated; E2F4 and E2F5 negatively regulate
cell cycle with decisions of cell differentiation and quiescence; and E2F6-8 are Rbindependent transcriptional repressors. Gene expression microarray analyses have
revealed that E2F3 regulates not only DNA replication for S phase entry, but also mitotic
regulatory factors such as cyclin B1, cyclin A2 and cdc2 during G2/M progression (1214). Our data show that ectopic expression of E2F3 induces mRNA and protein levels of
Aurora-A whereas knockdown of E2F3 decreases Aurora-A expression and mitotic cell
cycle delay. Notably, chromatin immunoprecipitation reveals that E2F3 binds to AuroraA promoter in vivo and the interaction primarily occurs during G2/M phase.
Moreover, we demonstrated frequent co-existence of elevated levels of E2F3 and
Aurora-A in human primary ovarian carcinoma. Importance of Aurora-A and E2F3 in
oncogenesis has been well established by their alterations in human neoplasms and their
capacity to induce cell transformation (15-18). We observed strong association of
elevated E2F3 expression and Aurora-A in ovarian tumors underscoring the clinical
significance of the E2F3-Aurora-A signaling axis. E2F3 could also be one of the major
transcriptional factors that contribute to upregulation of Aurora-A in other human
primary tumors. Aurora-A, as a mitotic E2F3 target gene, could mediate E2F3 oncogenic
function. Thus, E2F3-Aurora-A axis represents an attractive target for cancer therapy.
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CHFR (checkpoint with forkhead and ring finger) has been discovered as an early
mitosis checkpoint. Unlike the spindle checkpoint, the CHFR checkpoint is not essential
for cell proliferation, which can be explained by the high frequency of CHFR inactivation,
either by promoter methylation or in a few cases by missense mutations. The overall
CHFR inactivation rate is ranging from 15 to 50% in various tumor types (19-26), which
is much higher than the frequency of inactivation of all spindle checkpoint genes
combined.
It has been shown that CHFR mediates the degradation of polo-like kinase
1(Plk1), Aurora-A and CHFR itself through its ring finger domain which possesses
ubiquitin ligase activity. CHFR also contains a FHA domain, which could bind
phosphorylated peptides (19, 27), suggesting that protein kinases might act upstream of
CHFR and regulate its activity. A previous report shows that Akt/PKB phosphorylates
CHFR at Thr-39 in FHA domain after DNA damage, which led to inhibition of CHFR E3
activity and shortening G2 arrest induced by DNA damage (28). We demonstrated in this
study that CHFR is a substrate of Aurora-A kinase. Aurora-A phosphorylates CHFR at
Ser218 and Ser337 and inhibits its E3 activity.
We also showed that frequent downregulation of CHFR and inverse correlation of
expression of Aurora-A and CHFR in human ovarian cancer, which supports the notion
that CHFR is an E3 ligase of Aurora-A (29). However, co-expression of CHFR and
elevated Aurora-A was observed in a subset of ovarian cancers, which is consistent with
the previous findings that only a fraction of tumors with loss of CHFR expression are due
to promoter hypermethylation, suggesting that Aurora-A might phosphorylate CHFR and
inhibit its tumor suppressor function in these tumors. Taken together, these findings
indicate a feedback regulation loop between Aurora-A and CHFR.
Aurora-A exerts its mitotic function through regulation of a number of proteins
(30-34), which include histone H3, TACC3, Eg5, CPEB and TPX2. We and others have
previously shown Aurora-A phosphorylation of p53 which leads to inactivation of p53
and G2/M cell cycle progression (35). CHFR has been shown to mediate a delay in cell
cycle progression early in mitosis in response to microtubule stress. Identification of
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Aurora-A inhibition of CHFR provides additional molecular mechanism for Aurora-A
function in control of G2/M cell cycle progression.
Aurora-A has well-established but perhaps not yet fully understood roles in
centrosome maturation and duplication, mitotic entry and bipolar spindle assembly. By
the G2 phase of the cell cycle through anaphase, it can be detected in the centrosomes,
spindle poles and spindle microtubules. Following initial activation by the LIM protein
Ajuba in G2, Aurora-A phosphorylates and recruits several microtubule-associated
proteins to the centrosome to promote maturation. Cyclin-dependent kinases (CDKs)
require not only phosphorylation of the equivalent threonine (Thr160CDK) but also the
binding by a partner protein, cyclin A, to be fully activated (36). Aurora-A might also
rely on a similar mechanism. After nuclear envelope breakdown, Aurora-A is localized to
spindle microtubules and fully activated by its interacting non-enzymatic protein TPX2,
which plays an as yet not fully defined role in the Ran-spindle assembly process (37, 38).
The activation of Aurora-A is also facilitated by other cofactors/substrates, with different
regulatory mechanism and cellular functions.
We identified CNTD2, a novel mammalian B-type cyclin, as a cofactor of
Aurora-A. CNTD2 colocalizes and immunoprecipitates with Aurora-A at centrosome.
The interaction results in stabilization Aurora-A protein and activation of Aurora-A
kinase. Unlike other Aurora-A interaction proteins TPX2, Bora and Ajuba, which are also
substrates of the kinase (34, 39, 40), CNTD2 increases Aurora-A protein stability and
kinase activity but is not phosphorylated by Aurora-A.
Aurora-A is required for the activation and recruitment of cdc2-cyclin B1 to the
centrosome. The activated cdc2-cyclin B1 then commits the cell to mitosis (40). While
CNTD2 interacts with Aurora-A and activates Aurora-A and cdc2 kinase activity, it did
not form complex with cdc2. Other than the role in Aurora-A regulation, CNTD2 is an
oncogene, which is concluded from the facts that ectopic expression of CNTD2 induces
malignant transformation, centrosome amplification and genomic instability.
CNTD2 locates to chromosome 19q13 amplicon, which contains several other
oncogenes AKT2, PAK4, pancreatic differentiation 2 (PD2), SERTAD3 and
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transcriptional regulator intersex-like (IXL) (41-45). We have previously shown
amplification/overexpression of AKT2 in human ovarian, pancreatic and breast cancers.
Inhibition of AKT2 reduces tumor growth and sensitizes cells to chemotherapeutic agentinduced cell death (41, 46, 47). In this report, we demonstrated that CNTD2 is
amplified/overexpressed in human ovarian, pancreatic and lung cancers. Overexpression
of CNTD2 is associated with late stage/high grade ovarian tumors and accompanied with
poor clinic outcome. Therefore, CNTD2 could be a potential therapeutic target or cancer
progression/prognosis marker for these malignancies. The molecular mechanism of
CNTD2 regulation of Aurora-A protein stability and kinase activity remains to be
investigated.

Fig. 5.1. Working scheme of molecular mechanism of Aurora-A in human
oncogenesis. This dissertation has demonstrated that transcriptional upregulation by
E2F3, interaction and activation by CNTD2 of Aurora-A; and Aurora-A feedback
regulation of CHFR may contribute to Aurora-A-induced tumorigenesis.
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